

09/832,929

CofC



PATENT
Customer No. 22,852
Attorney Docket No. 6832.0013

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re U.S. Patent No.: 6,926,898)
Inventors:)
Craig A. Rosen and William A. Haseltine)
Issue Date.: August 9, 2005)
For: ALBUMIN FUSION PROTEINS)
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

REQUEST FOR CERTIFICATE OF CORRECTION

Pursuant to 35 U.S.C. §§ 254 and 255, and 37 C.F.R. §§ 1.322 and 1.323, this is a request for a Certificate of Correction in the above-identified patent. Some of the mistakes identified in the appended Form occurred through the fault of the Patent Office, as clearly disclosed by the records of the application which matured into this patent.

For example, the priority claims to Provisional Application Nos. 60/256,931, filed December 21, 2000; 60/199,384, filed April 25, 2000; and 60/229,358, filed April 12, 2000, were deleted in an Amendment filed February 4, 2004, and a Corrected Filing Receipt reflecting the change was mailed by the PTO on ~~February 13, 2004~~. However, ^{12/28/2005 MBEYENE1 00000018 6926898}
~~01 FC:1811~~ ^{100.00 op} the issued patent was printed with the priority claims in the title page under item (60).

Furthermore, the omitted U.S. Patent Documents under item (56) (References Cited) in the title page, were cited by Applicants in an Information Disclosure Statement

JAN 04 2006

filed April 5, 2004, and the Office returned the initialed Form PTO 1449 with the Supplemental Notice of Allowance mailed June 29, 2004.

The omitted OTHER PUBLICATIONS under item (56) (References Cited) in the title page, were also cited by Applicants in the Information Disclosure Statement filed April 5, 2004, and the Office returned the initialed Form PTO 1449 by facsimile on July 23, 2004.

The issued patent was printed without the Examiner's Amendment to the specification mailed March 3, 2005, with the Supplemental Notice of Allowance. The attached Certificate of Correction amends the specification according to the Examiner's Amendment.

Furthermore, the issued patent reflects the original Sequence Listing filed rather than the Substitute Sequence Listing submitted on August 20, 2004. The Sequence Listing in the attached Certificate of Correction is identical to the Substitute Sequence Listing filed on August 20, 2004, and is also identical to the computer readable copy of the Substitute Sequence Listing also submitted on August 20, 2004. Thus, the correction contains no new matter.

Other mistakes identified in the appended Form are of a clerical or typographical nature, or of minor character, and resulted from an error made in good faith by patentees. A check in the amount of \$100 (the fee set forth in 37 C.F.R. § 1.20(a)) is attached. Should a check not be appended or should any additional fees be needed, authorization is hereby given to charge any fees due in connection with the filing of this request to Deposit Account No. 06-0916.

Two (2) copies of PTO Form 1050 are appended. The complete Certificate of Correction involves thirty-five (35) pages. Issuance of the Certificate of Correction containing the correction is earnestly requested.

Please charge any required fees not included herewith to our deposit account 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: December 23, 2005

By: Charles E. Van Horn
Charles E. Van Horn
Reg. No. 40,266

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. 6,926,898

Page 1 of 35

APPLICATION NO.: 09/832,929

ISSUE DATE: August 9, 2005

INVENTOR(S): Craig A. Rosen and William A. Haseltine

It is hereby certified that an error or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Under item (60) (Related U.S. Application Data) of the title page, delete the text beginning with "Provisional application No. 60/256,931" to and ending "provisional application No. 60/229,358, filed on Apr. 12, 2000."

Under item (56) (References Cited) of the title page and under U.S. PATENT DOCUMENTS beginning on page 1, insert:

--	2003-0022308 A1	1/2003	Fleer et al.
	2003-0036170 A1	2/2003	Fleer et al.
	2003-0036171 A1	2/2003	Fleer et al.
	2003-0036172 A1	2/2003	Fleer et al.
	2003-0054554 A1	3/2003	Becquart et al.
	2003-0082747 A1	5/2003	Fleer et al.
	2003-0104578 A1	10/2001	Ballance
	2004-0010134 A1	4/2001	Rosen et al.
	09/832,501	4/2001	Ballance et al.
	09/833,041	4/2001	Rosen et al.
	09/833,111	4/2001	Rosen et al.
	09/833,117	4/2001	Rosen et al.
	09/833,118	4/2001	Rosen et al.
	10/702,536	11/2003	Fleer et al.
	10/702,636	11/2003	Fleer et al. --

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

Page 1 of 35

JAN 04 2006

Under item (56) (References Cited) of the title page and under OTHER PUBLICATIONS beginning on page 1, insert:

- Larsson, M., et al., "Role of Annexins in Endocytosis of Antigens in Immature Human Dendritic Cells," *Immunology* 92:501-511 (1997).
- Latta, M. et al., "Synthesis and Purification of Mature Human Serum Albumin From *E. Coli*," *Bio/Technology* 5:1309-1314 (1987).
- Latta, M., et al., "Tryptophan Promoter Derivatives on Multicopy Plasmids: A Comparative Analysis of Expression Potentials in *Escherichia coli*," *DNA and Cell Biology* 9:129-137 (1990).
- Lawn, R.M., et al., "The Sequence of Human Serum Albumin cDNA and its Expression in *E. coli*," *Nucleic Acids Research* 9:6103-6113 (1981).
- Le Bras, M., et al., "Epidemiologie et Clinique des Maladies Tropicales D'importation," *La Revue de Medicine Interne* 13:205-210 (1992), with English translation.
- Leblois, H., et al., "Stable Transduction of Actively Dividing Cells via a Novel Adenoviral/Episomal Vector," *Molecular Therapy* 1:314-322 (2000).
- Lee, C-H., et al., "Sodium Pertechnetate Tc99m Antral Scan in the Diagnosis of Retained Gastric Antrum," *Arch. Surg.* 119: 309-311 (1984).
- Lee, C-L., et al., "Preparation and Characterization of Polyethylene-Glycol-Modified Salmon Calcitonins," *Pharmaceutical Development and Technology*, 4(2): 269-275 (1999).
- Lee, W-C., et al., "Identification and Characterization of a Nuclear Localization Sequence-Binding Protein in Yeast," *Proc. Natl. Acad. Sci. USA* 86:8808-8812 (1989).
- Lee, Y-H., et al., "Comparison of Effective Renal Plasma Flow (ERPF) and Endogenous Creatinine Clearance (Ccr) in Evaluation of the Differential Kidney Function: An in Vivo Study," *Chin. Med. J. (Taipei)* 49:147-152 (1992).
- Lei, H-Y., et al., "An Antigen-specific Hypersensitivity Which Does Not Fit Into Traditional Classification of Hypersensitivity," *The Journal of Immunology* 143:432-438 (1989).
- Levitt, D., et al., "Toxicity of Perfluorinated Fatty-Acids for Human and Murine B Cell Lines," *Toxicology and Applied Pharmacology* 86:1-11 (1986).

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

Lew D.B., et al., "Mitogenic Effect of Lysosomal Hydrolases on Bovine Tracheal Myocytes in Culture," *The Journal of Clinical Investigation* 88:1969-1975 (1991).

Lewis, C., et al., "Is Sexual Dysfunction in Hypertensive Women Uncommon or Understudied?" *American Journal of Hypertension*, 11:733-735 (1998). --

Under item (57) (ABSTRACT) of the title page, "disordrs" should read --disorders--.

In the Specification

Col. 143, line 26, delete "As exhibited in Table 2, most", and insert --Most--.

Col. 143, line 31, delete "Table 2".

In the Claims

Col. 340, line 40, delete "an".

Col. 340, line 47, delete "an".

In the Sequence Listing

Delete the Sequence Listing beginning in Col. 299, beginning with the text "<160> NUMBER OF SEQ ID NOS: 72" to and ending "<400> SEQUENCE: 72"

Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser
1 5 10 15"

in Col. 340 and insert the following Sequence Listing:

```
<160> NUMBER OF SEQ ID NOS: 82

<210> 1
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<221> primer_bind
<223> primer useful to clone human growth hormone cDNA

<400> 1
cccaagaatt cccttatcca ggc 23

<210> 2
<211> 33
<212> DNA
<213> Artificial Sequence
<220>
<221> primer_bind
```

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

<223> primer useful to clone human growth hormone cDNA	
<400> 2 gggaagctta gaagccacag gatccctcca cag	33
<210> 3 <211> 16 <212> DNA <213> Artificial Sequence <220> <221> misc_structure <223> synthetic oligonucleotide used to join DNA fragments with non-cohesive ends.	
<400> 3 gataaagatt cccaac	16
<210> 4 <211> 17 <212> DNA <213> Artificial Sequence <220> <221> misc_structure <223> synthetic oligonucleotide used to join DNA fragments with non-cohesive ends.	
<400> 4 aattgttggg aatcttt	17
<210> 5 <211> 17 <212> DNA <213> Artificial Sequence <220> <221> misc_structure <223> synthetic oligonucleotide used to join DNA fragments with non-cohesive ends.	
<400> 5 ttaggcttat tcccaaac	17
<210> 6 <211> 18 <212> DNA <213> Artificial Sequence <220> <221> misc_structure <223> synthetic oligonucleotide used to join DNA fragments with non-cohesive ends.	
<400> 6 aattgttggg aataagcc	18

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

JAN 04 2006

```

<210> 7
<211> 24
<212> PRT
<213> Artificial Sequence
<220>
<221> SITE
<222> 1)..(19)
<223> invertase leader sequence
<220>
<221> SITE
<222> 20)..(24)
<223> first 5 amino acids of mature human serum albumin

<400> 7
Met Leu Leu Gln Ala Phe Leu Phe Leu Leu Ala Gly Phe Ala Ala Lys
    1           5                 10                15

Ile Ser Ala Asp Ala His Lys Ser
    20

<210> 8
<211> 21
<212> DNA
<213> Artificial Sequence
<220>
<221> misc_structure
<223> synthetic oligonucleotide used to join DNA fragments with non-cohesive ends.

<400> 8
gagatgcaca cctgagtgag g                                21

<210> 9
<211> 27
<212> DNA
<213> Artificial Sequence
<220>
<221> misc_structure
<223> synthetic oligonucleotide used to join DNA fragments with non-cohesive ends.

<400> 9
gatcctgtgg cttcgatgca cacaaga                                27

<210> 10
<211> 24
<212> DNA
<213> Artificial Sequence
<220>
<221> misc_structure
<223> synthetic oligonucleotide used to join DNA fragments with non-cohesive ends.

```

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

<400> 10		
ctcttgtgtg catcgaagcc acag		24
<210> 11		
<211> 30		
<212> DNA		
<213> Artificial Sequence		
<220>		
<221> misc_structure		
<223> synthetic oligonucleotide used to join DNA fragments with non-cohesive ends.		
<400> 11		
tgtggaagag cctcagaatt tattcccaac		30
<210> 12		
<211> 31		
<212> DNA		
<213> Artificial Sequence		
<220>		
<221> misc_structure		
<223> synthetic oligonucleotide used to join DNA fragments with non-cohesive ends.		
<400> 12		
aattgttggg aataaattct gaggctcttc c		31
<210> 13		
<211> 47		
<212> DNA		
<213> Artificial Sequence		
<220>		
<221> misc_structure		
<223> synthetic oligonucleotide used to join DNA fragments with non-cohesive ends.		
<400> 13		
ttaggcttag gtggcggtgg atccggcggt ggtggatctt tcccaac		47
<210> 14		
<211> 48		
<212> DNA		
<213> Artificial Sequence		
<220>		
<221> misc_structure		
<223> synthetic oligonucleotide used to join DNA fragments with non-cohesive ends.		
<400> 14		
aattgttggg aaagatccac caccgcccga tccaccgcac cctaagcc		48

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
 Garrett & Dunner, L.L.P.
 901 New York Avenue, N.W.
 Washington, D.C. 20001-4413

```

<210> 15
<211> 62
<212> DNA
<213> Artificial Sequence
<220>
<221> misc_structure
<223> synthetic oligonucleotide used to join DNA
fragments with non-cohesive ends.

<400> 15
ttaggcttag gcgggtgg atctggtggc ggcggatctg gtggcggtgg atccttccca 60
ac 62

<210> 16
<211> 63
<212> DNA
<213> Artificial Sequence
<220>
<221> misc_structure
<223> synthetic oligonucleotide used to join DNA
fragments with non-cohesive ends.

<400> 16
aattgttggg aaggatccac cgccaccaga tccggcccca ccagatccac caccgcctaa 60
gcc 63

<210> 17
<211> 1782
<212> DNA
<213> Homo sapiens
<220>
<221> CDS
<222> (1)..(1755)

<400> 17
gat gca cac aag agt gag gtt gct cat cgg ttt aaa gat ttg gga gaa 48
Asp Ala His Lys Ser Glu Val Ala His Arg Phe Lys Asp Leu Gly Glu
1 5 10 15

gaa aat ttc aaa gcc ttg gtg att gcc ttt gct cag tat ctt cag 96
Glu Asn Phe Lys Ala Leu Val Leu Ile Ala Phe Ala Gln Tyr Leu Gln
20 25 30

cag tgt cca ttt gaa gat cat gta aaa tta gtg aat gaa gta act gaa 144
Gln Cys Pro Phe Glu Asp His Val Lys Leu Val Asn Glu Val Thr Glu
35 40 45

ttt gca aaa aca tgt gtt gct gat gag tca gct gaa aat tgt gac aaa 192
Phe Ala Lys Thr Cys Val Ala Asp Glu Ser Ala Glu Asn Cys Asp Lys
50 55 60

```

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

tca ctt cat acc ctt ttt gga gac aaa tta tgc aca gtt gca act ctt		240
Ser Leu His Thr Leu Phe Gly Asp Lys Leu Cys Thr Val Ala Thr Leu		
65	70	75
85	90	95
cgt gaa acc tat ggt gaa atg gct gac tgc tgt gca aaa caa gaa cct		288
Arg Glu Thr Tyr Gly Glu Met Ala Asp Cys Cys Ala Lys Gln Glu Pro		
100	105	110
gag aga aat gaa tgc ttc ttg caa cac aaa gat gac aac cca aac ctc		336
Glu Arg Asn Glu Cys Phe Leu Gln His Lys Asp Asp Asn Pro Asn Leu		
115	120	125
ccc cga ttg gtg aga cca gag gtt gat gtg atg tgc act gct ttt cat		384
Pro Arg Leu Val Arg Pro Glu Val Asp Val Met Cys Thr Ala Phe His		
130	135	140
gac aat gaa gag aca ttt ttg aaa aaa tac tta tat gaa att gcc aga		432
Asp Asn Glu Glu Thr Phe Leu Lys Lys Tyr Leu Tyr Glu Ile Ala Arg		
145	150	155
160		
tat aaa gct gct ttt aca gaa tgt tgc caa gct gct gat aaa gct gcc		528
Tyr Lys Ala Ala Phe Thr Glu Cys Cys Gln Ala Ala Asp Lys Ala Ala		
165	170	175
tgc ctg ttg cca aag ctc gat gaa ctt cg ^g gat gaa ggg aag gct tcg		576
Cys Leu Leu Pro Lys Leu Asp Glu Leu Arg Asp Glu Gly Lys Ala Ser		
180	185	190
tct gcc aaa cag aga ctc aaa tgt gcc agt ctc caa aaa ttt gga gaa		624
Ser Ala Lys Gln Arg Leu Lys Cys Ala Ser Leu Gln Lys Phe Gly Glu		
195	200	205
aga gct ttc aaa gca tgg gca gtg gct cgc ctg agc cag aga ttt ccc		672
Arg Ala Phe Lys Ala Trp Ala Val Ala Arg Leu Ser Gln Arg Phe Pro		
210	215	220
aaa gct gag ttt gca gaa gtt tcc aag tta gtg aca gat ctt acc aaa		720
Lys Ala Glu Phe Ala Glu Val Ser Lys Leu Val Thr Asp Leu Thr Lys		
225	230	235
240		
gtc cac acg gaa tgc tgc cat gga gat ctg ctt gaa tgt gct gat gac		768
Val His Thr Glu Cys Cys His Gly Asp Leu Leu Glu Cys Ala Asp Asp		
245	250	255
agg gcg gac ctt gcc aag tat atc tgt gaa aat cag gat tcg atc tcc		816
Arg Ala Asp Leu Ala Lys Tyr Ile Cys Glu Asn Gln Asp Ser Ile Ser		
260	265	270

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

JAN 04 2006

agt aaa ctg aag gaa tgc tgt gaa aaa cct ctg ttg gaa aaa tcc cac		864	
Ser Lys Leu Lys Glu Cys Cys Glu Lys Pro Leu Leu Glu Lys Ser His			
275	280	285	
tgc att gcc gaa gtg gaa aat gat gag atg cct gct gac ttg cct tca		912	
Cys Ile Ala Glu Val Glu Asn Asp Glu Met Pro Ala Asp Leu Pro Ser			
290	295	300	
tta gct gct gat ttt gtt gaa agt aag gat gtt tgc aaa aac tat gct		960	
Leu Ala Ala Asp Phe Val Glu Ser Lys Asp Val Cys Lys Asn Tyr Ala			
305	310	315	320
gag gca aag gat gtc ttc ctg ggc atg ttt ttg tat gaa tat gca aga		1008	
Glu Ala Lys Asp Val Phe Leu Gly Met Phe Leu Tyr Glu Tyr Ala Arg			
325	330	335	
agg cat cct gat tac tct gtc gtg ctg ctg aga ctt gcc aag aca		1056	
Arg His Pro Asp Tyr Ser Val Val Leu Leu Leu Arg Leu Ala Lys Thr			
340	345	350	
tat gaa acc act cta gag aag tgc tgt gcc gct gca gat cct cat gaa		1104	
Tyr Glu Thr Thr Leu Glu Lys Cys Cys Ala Ala Asp Pro His Glu			
355	360	365	
tgc tat gcc aaa gtg ttc gat gaa ttt aaa cct ctt gtg gaa gag cct		1152	
Cys Tyr Ala Lys Val Phe Asp Glu Phe Lys Pro Leu Val Glu Glu Pro			
370	375	380	
cag aat tta atc aaa caa aac tgt gag ctt ttt gag cag ctt gga gag		1200	
Gln Asn Leu Ile Lys Gln Asn Cys Glu Leu Phe Glu Gln Leu Gly Glu			
385	390	395	400
tac aaa ttc cag aat gcg cta tta gtt cgt tac acc aag aaa gta ccc		1248	
Tyr Lys Phe Gln Asn Ala Leu Leu Val Arg Tyr Thr Lys Lys Val Pro			
405	410	415	
caa gtg tca act cca act ctt gta gag gtc tca aga aac cta gga aaa		1296	
Gln Val Ser Thr Pro Thr Leu Val Glu Val Ser Arg Asn Leu Gly Lys			
420	425	430	
gtg ggc agc aaa tgt tgt aaa cat cct gaa gca aaa aga atg ccc tgt		1344	
Val Gly Ser Lys Cys Cys Lys His Pro Glu Ala Lys Arg Met Pro Cys			
435	440	445	
gca gaa gac tat cta tcc gtg gtc ctg aac cag tta tgt gtg ttg cat		1392	
Ala Glu Asp Tyr Leu Ser Val Val Leu Asn Gln Leu Cys Val Leu His			
450	455	460	
gag aaa acg cca gta agt gac aga gtc aca aaa tgc tgc aca gag tcc		1440	
Glu Lys Thr Pro Val Ser Asp Arg Val Thr Lys Cys Cys Thr Glu Ser			
465	470	475	480

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

ttg gtg aac agg cga cca tgc ttt tca gct ctg gaa gtc gat gaa aca	1488																																																																																															
Leu Val Asn Arg Arg Pro Cys Phe Ser Ala Leu Glu Val Asp Glu Thr																																																																																																
485	490	495		tac gtt ccc aaa gag ttt aat gct gaa aca ttc acc ttc cat gca gat	1536	Tyr Val Pro Lys Glu Phe Asn Ala Glu Thr Phe Thr Phe His Ala Asp		500	505	510		ata tgc aca ctt tct gag aag gag aga caa atc aag aaa caa act gca	1584	Ile Cys Thr Leu Ser Glu Lys Glu Arg Gln Ile Lys Lys Gln Thr Ala		515	520	525		ctt gtt gag ctt gtg aaa cac aag ccc aag gca aca aaa gag caa ctg	1632	Leu Val Glu Leu Val Lys His Lys Pro Lys Ala Thr Lys Glu Gln Leu		530	535	540		aaa gct gtt atg gat gat ttc gca gct ttt gta gag aag tgc tgc aag	1680	Lys Ala Val Met Asp Asp Phe Ala Ala Phe Val Glu Lys Cys Cys Lys		545	550	555	560	gct gac gat aag gag acc tgc ttt gcc gag gag ggt aaa aaa ctt gtt	1728	Ala Asp Asp Lys Glu Thr Cys Phe Ala Glu Glu Gly Lys Lys Leu Val		565	570	575		gct gca agt caa gct gcc tta ggc tta taacatctac atttaaaagc atctcag	1782	Ala Ala Ser Gln Ala Ala Leu Gly Leu		580	585		<210> 18		<211> 585		<212> PRT		<213> Homo Sapiens		<400> 18		Asp Ala His Lys Ser Glu Val Ala His Arg Phe Lys Asp Leu Gly Glu		1	5	10	15	Glu Asn Phe Lys Ala Leu Val Leu Ile Ala Phe Ala Gln Tyr Leu Gln		20	25	30		Gln Cys Pro Phe Glu Asp His Val Lys Leu Val Asn Glu Val Thr Glu		35	40	45		Phe Ala Lys Thr Cys Val Ala Asp Glu Ser Ala Glu Asn Cys Asp Lys		50	55	60		Ser Leu His Thr Leu Phe Gly Asp Lys Leu Cys Thr Val Ala Thr Leu		65	70	75	80	Arg Glu Thr Tyr Gly Glu Met Ala Asp Cys Cys Ala Lys Gln Glu Pro		85	90	95	
495																																																																																																
tac gtt ccc aaa gag ttt aat gct gaa aca ttc acc ttc cat gca gat	1536																																																																																															
Tyr Val Pro Lys Glu Phe Asn Ala Glu Thr Phe Thr Phe His Ala Asp																																																																																																
500	505	510		ata tgc aca ctt tct gag aag gag aga caa atc aag aaa caa act gca	1584	Ile Cys Thr Leu Ser Glu Lys Glu Arg Gln Ile Lys Lys Gln Thr Ala		515	520	525		ctt gtt gag ctt gtg aaa cac aag ccc aag gca aca aaa gag caa ctg	1632	Leu Val Glu Leu Val Lys His Lys Pro Lys Ala Thr Lys Glu Gln Leu		530	535	540		aaa gct gtt atg gat gat ttc gca gct ttt gta gag aag tgc tgc aag	1680	Lys Ala Val Met Asp Asp Phe Ala Ala Phe Val Glu Lys Cys Cys Lys		545	550	555	560	gct gac gat aag gag acc tgc ttt gcc gag gag ggt aaa aaa ctt gtt	1728	Ala Asp Asp Lys Glu Thr Cys Phe Ala Glu Glu Gly Lys Lys Leu Val		565	570	575		gct gca agt caa gct gcc tta ggc tta taacatctac atttaaaagc atctcag	1782	Ala Ala Ser Gln Ala Ala Leu Gly Leu		580	585		<210> 18		<211> 585		<212> PRT		<213> Homo Sapiens		<400> 18		Asp Ala His Lys Ser Glu Val Ala His Arg Phe Lys Asp Leu Gly Glu		1	5	10	15	Glu Asn Phe Lys Ala Leu Val Leu Ile Ala Phe Ala Gln Tyr Leu Gln		20	25	30		Gln Cys Pro Phe Glu Asp His Val Lys Leu Val Asn Glu Val Thr Glu		35	40	45		Phe Ala Lys Thr Cys Val Ala Asp Glu Ser Ala Glu Asn Cys Asp Lys		50	55	60		Ser Leu His Thr Leu Phe Gly Asp Lys Leu Cys Thr Val Ala Thr Leu		65	70	75	80	Arg Glu Thr Tyr Gly Glu Met Ala Asp Cys Cys Ala Lys Gln Glu Pro		85	90	95									
510																																																																																																
ata tgc aca ctt tct gag aag gag aga caa atc aag aaa caa act gca	1584																																																																																															
Ile Cys Thr Leu Ser Glu Lys Glu Arg Gln Ile Lys Lys Gln Thr Ala																																																																																																
515	520	525		ctt gtt gag ctt gtg aaa cac aag ccc aag gca aca aaa gag caa ctg	1632	Leu Val Glu Leu Val Lys His Lys Pro Lys Ala Thr Lys Glu Gln Leu		530	535	540		aaa gct gtt atg gat gat ttc gca gct ttt gta gag aag tgc tgc aag	1680	Lys Ala Val Met Asp Asp Phe Ala Ala Phe Val Glu Lys Cys Cys Lys		545	550	555	560	gct gac gat aag gag acc tgc ttt gcc gag gag ggt aaa aaa ctt gtt	1728	Ala Asp Asp Lys Glu Thr Cys Phe Ala Glu Glu Gly Lys Lys Leu Val		565	570	575		gct gca agt caa gct gcc tta ggc tta taacatctac atttaaaagc atctcag	1782	Ala Ala Ser Gln Ala Ala Leu Gly Leu		580	585		<210> 18		<211> 585		<212> PRT		<213> Homo Sapiens		<400> 18		Asp Ala His Lys Ser Glu Val Ala His Arg Phe Lys Asp Leu Gly Glu		1	5	10	15	Glu Asn Phe Lys Ala Leu Val Leu Ile Ala Phe Ala Gln Tyr Leu Gln		20	25	30		Gln Cys Pro Phe Glu Asp His Val Lys Leu Val Asn Glu Val Thr Glu		35	40	45		Phe Ala Lys Thr Cys Val Ala Asp Glu Ser Ala Glu Asn Cys Asp Lys		50	55	60		Ser Leu His Thr Leu Phe Gly Asp Lys Leu Cys Thr Val Ala Thr Leu		65	70	75	80	Arg Glu Thr Tyr Gly Glu Met Ala Asp Cys Cys Ala Lys Gln Glu Pro		85	90	95																	
525																																																																																																
ctt gtt gag ctt gtg aaa cac aag ccc aag gca aca aaa gag caa ctg	1632																																																																																															
Leu Val Glu Leu Val Lys His Lys Pro Lys Ala Thr Lys Glu Gln Leu																																																																																																
530	535	540		aaa gct gtt atg gat gat ttc gca gct ttt gta gag aag tgc tgc aag	1680	Lys Ala Val Met Asp Asp Phe Ala Ala Phe Val Glu Lys Cys Cys Lys		545	550	555	560	gct gac gat aag gag acc tgc ttt gcc gag gag ggt aaa aaa ctt gtt	1728	Ala Asp Asp Lys Glu Thr Cys Phe Ala Glu Glu Gly Lys Lys Leu Val		565	570	575		gct gca agt caa gct gcc tta ggc tta taacatctac atttaaaagc atctcag	1782	Ala Ala Ser Gln Ala Ala Leu Gly Leu		580	585		<210> 18		<211> 585		<212> PRT		<213> Homo Sapiens		<400> 18		Asp Ala His Lys Ser Glu Val Ala His Arg Phe Lys Asp Leu Gly Glu		1	5	10	15	Glu Asn Phe Lys Ala Leu Val Leu Ile Ala Phe Ala Gln Tyr Leu Gln		20	25	30		Gln Cys Pro Phe Glu Asp His Val Lys Leu Val Asn Glu Val Thr Glu		35	40	45		Phe Ala Lys Thr Cys Val Ala Asp Glu Ser Ala Glu Asn Cys Asp Lys		50	55	60		Ser Leu His Thr Leu Phe Gly Asp Lys Leu Cys Thr Val Ala Thr Leu		65	70	75	80	Arg Glu Thr Tyr Gly Glu Met Ala Asp Cys Cys Ala Lys Gln Glu Pro		85	90	95																									
540																																																																																																
aaa gct gtt atg gat gat ttc gca gct ttt gta gag aag tgc tgc aag	1680																																																																																															
Lys Ala Val Met Asp Asp Phe Ala Ala Phe Val Glu Lys Cys Cys Lys																																																																																																
545	550	555	560	gct gac gat aag gag acc tgc ttt gcc gag gag ggt aaa aaa ctt gtt	1728	Ala Asp Asp Lys Glu Thr Cys Phe Ala Glu Glu Gly Lys Lys Leu Val		565	570	575		gct gca agt caa gct gcc tta ggc tta taacatctac atttaaaagc atctcag	1782	Ala Ala Ser Gln Ala Ala Leu Gly Leu		580	585		<210> 18		<211> 585		<212> PRT		<213> Homo Sapiens		<400> 18		Asp Ala His Lys Ser Glu Val Ala His Arg Phe Lys Asp Leu Gly Glu		1	5	10	15	Glu Asn Phe Lys Ala Leu Val Leu Ile Ala Phe Ala Gln Tyr Leu Gln		20	25	30		Gln Cys Pro Phe Glu Asp His Val Lys Leu Val Asn Glu Val Thr Glu		35	40	45		Phe Ala Lys Thr Cys Val Ala Asp Glu Ser Ala Glu Asn Cys Asp Lys		50	55	60		Ser Leu His Thr Leu Phe Gly Asp Lys Leu Cys Thr Val Ala Thr Leu		65	70	75	80	Arg Glu Thr Tyr Gly Glu Met Ala Asp Cys Cys Ala Lys Gln Glu Pro		85	90	95																																	
555	560																																																																																															
gct gac gat aag gag acc tgc ttt gcc gag gag ggt aaa aaa ctt gtt	1728																																																																																															
Ala Asp Asp Lys Glu Thr Cys Phe Ala Glu Glu Gly Lys Lys Leu Val																																																																																																
565	570	575		gct gca agt caa gct gcc tta ggc tta taacatctac atttaaaagc atctcag	1782	Ala Ala Ser Gln Ala Ala Leu Gly Leu		580	585		<210> 18		<211> 585		<212> PRT		<213> Homo Sapiens		<400> 18		Asp Ala His Lys Ser Glu Val Ala His Arg Phe Lys Asp Leu Gly Glu		1	5	10	15	Glu Asn Phe Lys Ala Leu Val Leu Ile Ala Phe Ala Gln Tyr Leu Gln		20	25	30		Gln Cys Pro Phe Glu Asp His Val Lys Leu Val Asn Glu Val Thr Glu		35	40	45		Phe Ala Lys Thr Cys Val Ala Asp Glu Ser Ala Glu Asn Cys Asp Lys		50	55	60		Ser Leu His Thr Leu Phe Gly Asp Lys Leu Cys Thr Val Ala Thr Leu		65	70	75	80	Arg Glu Thr Tyr Gly Glu Met Ala Asp Cys Cys Ala Lys Gln Glu Pro		85	90	95																																									
575																																																																																																
gct gca agt caa gct gcc tta ggc tta taacatctac atttaaaagc atctcag	1782																																																																																															
Ala Ala Ser Gln Ala Ala Leu Gly Leu																																																																																																
580	585																																																																																															
<210> 18																																																																																																
<211> 585																																																																																																
<212> PRT																																																																																																
<213> Homo Sapiens																																																																																																
<400> 18																																																																																																
Asp Ala His Lys Ser Glu Val Ala His Arg Phe Lys Asp Leu Gly Glu																																																																																																
1	5	10	15	Glu Asn Phe Lys Ala Leu Val Leu Ile Ala Phe Ala Gln Tyr Leu Gln		20	25	30		Gln Cys Pro Phe Glu Asp His Val Lys Leu Val Asn Glu Val Thr Glu		35	40	45		Phe Ala Lys Thr Cys Val Ala Asp Glu Ser Ala Glu Asn Cys Asp Lys		50	55	60		Ser Leu His Thr Leu Phe Gly Asp Lys Leu Cys Thr Val Ala Thr Leu		65	70	75	80	Arg Glu Thr Tyr Gly Glu Met Ala Asp Cys Cys Ala Lys Gln Glu Pro		85	90	95																																																																
10	15																																																																																															
Glu Asn Phe Lys Ala Leu Val Leu Ile Ala Phe Ala Gln Tyr Leu Gln																																																																																																
20	25	30		Gln Cys Pro Phe Glu Asp His Val Lys Leu Val Asn Glu Val Thr Glu		35	40	45		Phe Ala Lys Thr Cys Val Ala Asp Glu Ser Ala Glu Asn Cys Asp Lys		50	55	60		Ser Leu His Thr Leu Phe Gly Asp Lys Leu Cys Thr Val Ala Thr Leu		65	70	75	80	Arg Glu Thr Tyr Gly Glu Met Ala Asp Cys Cys Ala Lys Gln Glu Pro		85	90	95																																																																						
30																																																																																																
Gln Cys Pro Phe Glu Asp His Val Lys Leu Val Asn Glu Val Thr Glu																																																																																																
35	40	45		Phe Ala Lys Thr Cys Val Ala Asp Glu Ser Ala Glu Asn Cys Asp Lys		50	55	60		Ser Leu His Thr Leu Phe Gly Asp Lys Leu Cys Thr Val Ala Thr Leu		65	70	75	80	Arg Glu Thr Tyr Gly Glu Met Ala Asp Cys Cys Ala Lys Gln Glu Pro		85	90	95																																																																												
45																																																																																																
Phe Ala Lys Thr Cys Val Ala Asp Glu Ser Ala Glu Asn Cys Asp Lys																																																																																																
50	55	60		Ser Leu His Thr Leu Phe Gly Asp Lys Leu Cys Thr Val Ala Thr Leu		65	70	75	80	Arg Glu Thr Tyr Gly Glu Met Ala Asp Cys Cys Ala Lys Gln Glu Pro		85	90	95																																																																																		
60																																																																																																
Ser Leu His Thr Leu Phe Gly Asp Lys Leu Cys Thr Val Ala Thr Leu																																																																																																
65	70	75	80	Arg Glu Thr Tyr Gly Glu Met Ala Asp Cys Cys Ala Lys Gln Glu Pro		85	90	95																																																																																								
75	80																																																																																															
Arg Glu Thr Tyr Gly Glu Met Ala Asp Cys Cys Ala Lys Gln Glu Pro																																																																																																
85	90	95																																																																																														
95																																																																																																

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

Glu	Arg	Asn	Glu	Cys	Phe	Leu	Gln	His	Lys	Asp	Asp	Asn	Pro	Asn	Leu
100															110
Pro	Arg	Leu	Val	Arg	Pro	Glu	Val	Asp	Val	Met	Cys	Thr	Ala	Phe	His
115															125
Asp	Asn	Glu	Glu	Thr	Phe	Leu	Lys	Lys	Tyr	Leu	Tyr	Glu	Ile	Ala	Arg
130															140
Arg	His	Pro	Tyr	Phe	Tyr	Ala	Pro	Glu	Leu	Leu	Phe	Phe	Ala	Lys	Arg
145															160
Tyr	Lys	Ala	Ala	Phe	Thr	Glu	Cys	Cys	Gln	Ala	Ala	Asp	Lys	Ala	Ala
165															175
Cys	Leu	Leu	Pro	Lys	Leu	Asp	Glu	Leu	Arg	Asp	Glu	Gly	Lys	Ala	Ser
180															190
Ser	Ala	Lys	Gln	Arg	Leu	Lys	Cys	Ala	Ser	Leu	Gln	Lys	Phe	Gly	Glu
195															205
Arg	Ala	Phe	Lys	Ala	Trp	Ala	Val	Ala	Arg	Leu	Ser	Gln	Arg	Phe	Pro
210															220
Lys	Ala	Glu	Phe	Ala	Glu	Val	Ser	Lys	Leu	Val	Thr	Asp	Leu	Thr	Lys
225															240
Val	His	Thr	Glu	Cys	Cys	His	Gly	Asp	Leu	Leu	Glu	Cys	Ala	Asp	Asp
245															255
Arg	Ala	Asp	Leu	Ala	Lys	Tyr	Ile	Cys	Glu	Asn	Gln	Asp	Ser	Ile	Ser
260															270
Ser	Lys	Leu	Lys	Glu	Cys	Cys	Glu	Lys	Pro	Leu	Leu	Glu	Lys	Ser	His
275															285
Cys	Ile	Ala	Glu	Val	Glu	Asn	Asp	Glu	Met	Pro	Ala	Asp	Leu	Pro	Ser
290															300
Leu	Ala	Ala	Asp	Phe	Val	Glu	Ser	Lys	Asp	Val	Cys	Lys	Asn	Tyr	Ala
305															320
Glu	Ala	Lys	Asp	Val	Phe	Leu	Gly	Met	Phe	Leu	Tyr	Glu	Tyr	Ala	Arg
325															335
Arg	His	Pro	Asp	Tyr	Ser	Val	Val	Leu	Leu	Leu	Arg	Leu	Ala	Lys	Thr
340															350
Tyr	Glu	Thr	Thr	Leu	Glu	Lys	Cys	Cys	Ala	Ala	Asp	Pro	His	Glu	
355															365

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

Cys	Tyr	Ala	Lys	Val	Phe	Asp	Glu	Phe	Lys	Pro	Leu	Val	Glu	Glu	Pro
370					375						380				
Gln	Asn	Leu	Ile	Lys	Gln	Asn	Cys	Glu	Leu	Phe	Glu	Gln	Leu	Gly	Glu
385					390					395				400	
Tyr	Lys	Phe	Gln	Asn	Ala	Leu	Leu	Val	Arg	Tyr	Thr	Lys	Lys	Val	Pro
					405				410					415	
Gln	Val	Ser	Thr	Pro	Thr	Leu	Val	Glu	Val	Ser	Arg	Asn	Leu	Gly	Lys
					420				425				430		
Val	Gly	Ser	Lys	Cys	Cys	Lys	His	Pro	Glu	Ala	Lys	Arg	Met	Pro	Cys
					435			440				445			
Ala	Glu	Asp	Tyr	Leu	Ser	Val	Val	Leu	Asn	Gln	Leu	Cys	Val	Leu	His
					450			455			460				
Glu	Lys	Thr	Pro	Val	Ser	Asp	Arg	Val	Thr	Lys	Cys	Cys	Thr	Glu	Ser
					465			470			475			480	
Leu	Val	Asn	Arg	Arg	Pro	Cys	Phe	Ser	Ala	Leu	Glu	Val	Asp	Glu	Thr
					485			490			495				
Tyr	Val	Pro	Lys	Glu	Phe	Asn	Ala	Glu	Thr	Phe	Thr	Phe	His	Ala	Asp
					500			505			510				
Ile	Cys	Thr	Leu	Ser	Glu	Lys	Glu	Arg	Gln	Ile	Lys	Lys	Gln	Thr	Ala
					515			520			525				
Leu	Val	Glu	Leu	Val	Lys	His	Lys	Pro	Lys	Ala	Thr	Lys	Glu	Gln	Leu
					530			535			540				
Lys	Ala	Val	Met	Asp	Asp	Phe	Ala	Ala	Phe	Val	Glu	Lys	Cys	Cys	Lys
					545			550			555			560	
Ala	Asp	Asp	Lys	Glu	Thr	Cys	Phe	Ala	Glu	Glu	Gly	Lys	Lys	Leu	Val
					565			570			575				
Ala	Ala	Ser	Gln	Ala	Ala	Leu	Gly	Leu							
					580			585							
<210>	19														
<211>	58														
<212>	DNA														
<213>	Artificial Sequence														
<220>															
<221>	primer_bind														
<223>	primer used to generate XhoI and ClaI site in pPPC0006														
<400>	19														
gcctcgagaa	aagagatgca	cacaagagtg	aggttgctca	tcgatttaaa	gatttggg									58	

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

Page 12 of 35

JAN 04 2006

```

<210> 20
<211> 59
<212> DNA
<213> Artificial Sequence
<220>
<221> primer_bind
<223> primer used in generation XhoI and ClaI site in pPPC0006

<400> 20
aatcgatgag caacctcaact cttgtgtgca tctctttct cgaggctcct ggaataa 59

<210> 21
<211> 24
<212> DNA
<213> Artificial Sequence
<220>
<221> primer_bind
<223> primer used in generation XhoI and ClaI site in pPPC0006

<400> 21
tacaaaactta agagtccaaat tagc 24

<210> 22
<211> 29
<212> DNA
<213> Artificial Sequence
<220>
<221> primer_bind
<223> primer used in generation XhoI and ClaI site in pPPC0006

<400> 22
cacttctcta gagtggttc atatgtctt 29

<210> 23
<211> 60
<212> DNA
<213> Artificial Sequence
<220>
<221> Misc_Structure
<223> Synthetic oligonucleotide used to alter restriction sites in pPPC0007

<400> 23
aagctgcctt aggctataa taaggcgcbc cggccggccg tttaaactaa gcttaattct 60

<210> 24
<211> 60
<212> DNA
<213> Artificial Sequence
<220>
<221> Misc_Structure
<223> Synthetic oligonucleotide used to alter restriction sites in pPPC0007

```

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
 Garrett & Dunner, L.L.P.
 901 New York Avenue, N.W.
 Washington, D.C. 20001-4413

JAN 04 2006

```
<400> 24
agaattaagc ttagttaaa cggccggccg gcgcgccttataaggcctt aaggcagctt 60

<210> 25
<211> 32
<212> DNA
<213> Artificial Sequence
<220>
<221> primer_bind
<223> forward primer useful for generation of albumin fusion protein in which
the albumin moiety is N-terminal of the Therapeutic Protein
<220>
<221> misc feature
<222> (18)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (19)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (20)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (21)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (22)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (23)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (24)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (25)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (26)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (27)
<223> n equals a,t,g, or c
<220>
```

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

JAN 04 2006

```
<221> misc feature
<222> (28)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (29)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (30)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (31)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (32)
<223> n equals a,t,g, or c

<400> 25
aagctgcctt aggcttannn nnnnnnnnnn nn 32

<210> 26
<211> 51
<212> DNA
<213> Artificial Sequence
<220>
<221> primer_bind
<223> reverse primer useful for generation of albumin fusion protein in which
the albumin moiety is N-terminal of the Therapeutic Protein
<220>
<221> misc feature
<222> (37)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (38)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (39)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (40)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (41)
<223> n equals a,t,g, or c
<220>
```

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

JAN 04 2006.

```
<221> misc feature
<222> (42)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (43)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (44)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (45)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (46)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (47)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (48)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (49)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (50)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (51)
<223> n equals a,t,g, or c
```

<400> 26
gcgcgcgtt aaacggccgg ccggcgcgcc ttattannnn nnnnnnnnnn n

51

```
<210> 27
<211> 33
<212> DNA
<213> Artificial Sequence
<220>
<223> forward primer useful for generation of albumin fusion protein in which
the albumin moiety is c-terminal of the Therapeutic Protein
<220>
<221> misc feature
```

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

JAN 04 2006

```
<22> (19)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (20)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (21)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (22)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (23)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (24)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (25)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (26)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (27)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (28)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (29)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (30)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (31)
<223> n equals a,t,g, or c
<220>
<221> misc feature
```

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

JAN 04 2006

```
<222> (32)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (33)
<223> n equals a,t,g, or c

<400> 27
aggagcgtcg acaaaaagann nnnnnnnnnn nnn

<210> 28
<211> 52
<212> DNA
<213> Artificial Sequence
<220>
<221> primer_bind
<223> reverse primer useful for generation of albumin fusion protein in which
the albumin moiety is c-terminal of the Therapeutic Protein
<220>
<221> misc feature
<222> (38)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (39)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (40)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (41)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (42)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (43)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (44)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (45)
<223> n equals a,t,g, or c
<220>
<221> misc feature
```

33

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

JAN 04 2006

```

<222> (46)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (47)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (48)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (49)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (50)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (51)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (52)
<223> n equals a,t,g, or c

<400> 28
ctttaaatcg atgagcaacc tcactcttgt gtgcacnnnn nnnnnnnnnn nn      52

<210> 29
<211> 24
<212> PRT
<213> Artificial Sequence
<220>
<221> signal
<223> signal peptide of natural human serum albumin protein

<400> 29
Met Lys Trp Val Ser Phe Ile Ser Leu Leu Phe Leu Phe Ser Ser Ala
    1           5             10            15

Tyr Ser Arg Ser Leu Asp Lys Arg
    20

<210> 30
<211> 114
<212> DNA
<213> Artificial Sequence
<220>
<221> primer_bind
<223> forward primer useful for generation of PC4:HSA albumin fusion VECTOR

```

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
 Garrett & Dunner, L.L.P.
 901 New York Avenue, N.W.
 Washington, D.C. 20001-4413

JAN 04 2006

```

<220>
<221> misc_feature
<222> (5)..(10)
<223> BamHI restriction site
<220>
<221> misc_feature
<222> (11)..(16)
<223> Hind III restriction site
<220>
<221> misc_feature
<222> (17)..(27)
<223> Kozak sequence
<220>
<221> misc_feature
<222> (25)..(97)
<223> cds natural signal sequence of human serum albumin
<220>
<221> misc_feature
<222> (75)..(81)
<223> XhoI restriction site
<220>
<221> misc_feature
<222> (98)..(114)
<223> cds first six amino acids of human serum albumin

<400> 30
tcagggatcc aagcttccgc caccatgaag tggtaacct ttatttcctt tcttttctc 60
tttagctcggttactcgag gggtgtgttt cgtcgagatg cacacaagag tgtag 114

<210> 31
<211> 43
<212> DNA
<213> Artificial Sequence
<220>
<221> primer_bind
<223> reverse primer useful for generation of PC4:HSA albumin fusion VECTOR
<220>
<221> misc_feature
<222> (6)..(11)
<223> Asp718 restriction site
<220>
<221> misc_feature
<222> (12)..(17)
<223> EcoRI restriction site
<220>
<221> misc_feature
<222> (15)..(17)
<223> reverse complement of stop codon
<220>
<221> misc_feature
<222> (18)..(25)

```

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
 Garrett & Dunner, L.L.P.
 901 New York Avenue, N.W.
 Washington, D.C. 20001-4413

JAN 04 2006

```
<223> AsCI restriction site
<220>
<221> misc_feature
<222> (18)..(43)
<223> reverse complement of DNA sequence encoding last 9 amino acids

<400> 31
gcagcggtac cgaattcggc gcgccttata agcctaaggc agc 43

<210> 32
<211> 46
<212> DNA
<213> Artificial Sequence
<220>
<221> primer_bind
<223> forward primer useful for inserting Therapeutic protein into pC4:HSA
vector
<220>
<221> misc feature
<222> (29)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (30)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (31)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (32)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (33)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (34)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (35)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (36)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (37)
```

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

```
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (38)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (39)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (40)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (41)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (42)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (43)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (44)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (45)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (46)
<223> n equals a,t,g, or c

<400> 32
ccggcgctcg aggggtgtgt ttcgtcgann nnnnnnnnnn nnnnnn
```

46

```
<210> 33
<211> 55
<212> DNA
<213> Artificial Sequence
<220>
<221> primer_bind
<223> reverse primer useful for inserting Therapeutic protein into pC4:HSA
vector
<220>
<221> misc feature
<222> (38)
```

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

JAN 04 2006.

```
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (39)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (40)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (41)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (42)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (43)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (44)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (45)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (46)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (47)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (48)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (49)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (50)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (51)
```

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

JAN 04 2006

```

<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (52)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (53)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (54)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (55)
<223> n equals a,t,g, or c

<400> 33
agtccccatcg atgagcaacc tcactcttgt gtgcacnnnn nnnnnnnnnn nnnnn      55

<210> 34
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<221> signal
<223> Stanniocalcin signal peptide

<400> 34
Met Leu Gln Asn Ser Ala Val Leu Leu Leu Val Ile Ser Ala Ser Ala
    1           5                 10                  15

<210> 35
<211> 22
<212> PRT
<213> Artificial Sequence
<220>
<221> signal
<223> Synthetic signal peptide

<400> 35
Met Pro Thr Trp Ala Trp Trp Leu Phe Leu Val Leu Leu Leu Ala Leu
    1           5                 10                  15

Trp Ala Pro Ala Arg Gly
    20

<210> 36
<211> 23
<212> DNA
<213> Artificial Sequence
<220>

```

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

JAN 04 2006

```
<221>primer_bind
<223>Degenerate VH forward primer useful for amplifying human VH domains

<400> 36
caggtgcagc tggcagtc tgg 23

<210> 37
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate VH forward primer useful for amplifying human VH domains

<400> 37
caggtcaact taaggagtc tgg 23

<210> 38
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate VH forward primer useful for amplifying human VH domains

<400> 38
gaggtgcagc tggcagtc tgg 23

<210> 39
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate VH forward primer useful for amplifying human VH domains

<400> 39
caggtgcagc tgcaggagtc ggg 23

<210> 40
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate VH forward primer useful for amplifying human VH domains

<400> 40
gaggtgcagc tggcagtc tgc 23

<210> 41
<211> 23
```

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

JAN 04 2006

```

<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate VH forward primer useful for amplifying human VH domains

<400> 41
caggtacagc tgcagcagtc agg 23

<210> 42
<211> 24
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate JH reverse primer useful for amplifying human VH domains

<400> 42
tgaggagacg gtgaccaggg tgcc 24

<210> 43
<211> 24
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate JH reverse primer useful for amplifying human VH domains

<400> 43
tgaagagacg gtgaccattg tccc 24

<210> 44
<211> 24
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate JH reverse primer useful for amplifying human VH domains

<400> 44
tgaggagacg gtgaccaggg ttcc 24

<210> 45
<211> 24
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate JH reverse primer useful for amplifying human VH domains

<400> 45
tgaggagacg gtgaccgtgg tccc 24

```

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

JAN 04 2006

```

<210> 46
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate Vkappa forward primer useful for amplifying human VL domains

<400> 46
gacatccaga tgaccaggc tcc 23

<210> 47
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate Vkappa forward primer useful for amplifying human VL domains

<400> 47
gatgttgtga tgactcagtc tcc 23

<210> 48
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate Vkappa forward primer useful for amplifying human VL domains

<400> 48
gatattgtga tgactcagtc tcc 23

<210> 49
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate Vkappa forward primer useful for amplifying human VL domains

<400> 49
gaaatttgt tgacgcagtc tcc 23

<210> 50
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate Vkappa forward primer useful for amplifying human VL domains

```

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

JAN 04 2006

```

<400> 50
gacatcgta tgaccagtc tcc 23

<210> 51
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate Vkappa forward primer useful for amplifying human VL domains

<400> 51
gaaacgacac tcacgcagtc tcc 23

<210> 52
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate Vkappa forward primer useful for amplifying human VL domains

<400> 52
gaaattgtgc tgactcagtc tcc 23

<210> 53
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate Vlambda forward primer useful for amplifying human VL domains

<400> 53
cagtctgtgt tgacgcagcc gcc 23

<210> 54
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate Vlambda forward primer useful for amplifying human VL domains

<400> 54
cagtctgccc tgactcagcc tgc 23

<210> 55
<211> 23
<212> DNA
<213> Artificial Sequence
<220>

```

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

```

<221>primer_bind
<223>Degenerate Vlambda forward primer useful for amplifying human VL domains

<400> 55
tcctatgtgc tgactcagcc acc 23

<210> 56
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221>primer_bind
<223>Degenerate Vlambda forward primer useful for amplifying human VL domains

<400> 56
tcttctgagc tgactcagga ccc 23

<210> 57
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate Vlambda forward primer useful for amplifying human VL domains

<400> 57
cacgttatac tgactcaacc gcc 23

<210> 58
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate Vlambda forward primer useful for amplifying human VL domains

<400> 58
caggctgtgc tcactcagcc gtc 23

<210> 59
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate Vlambda forward primer useful for amplifying human VL domains

<400> 59
aattttatgc tgactcagcc cca 23

```

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

```
<210> 60
<211> 24
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate J kappa reverse primer useful for amplifying human VL domains

<400> 60
acgtttgatt tccacccttgg tccc 24

<210> 61
<211> 24
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate J kappa reverse primer useful for amplifying human VL domains

<400> 61
acgtttgatc tccagcttgg tccc 24

<210> 62
<211> 24
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate J kappa reverse primer useful for amplifying human VL domains

<400> 62
acgtttgata tccactttgg tccc 24

<210> 63
<211> 24
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate J kappa reverse primer useful for amplifying human VL domains

<400> 63
acgtttgatc tccacccttgg tccc 24

<210> 64
<211> 24
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate J kappa reverse primer useful for amplifying human VL domains
```

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

<400> 64	
acgtttaatc tccagtcgtg tccc	24
<210> 65	
<211> 23	
<212> DNA	
<213> Artificial Sequence	
<220>	
<221>primer_bind	
<223>Degenerate Jlambda reverse primer useful for amplifying human VL domains	
<400> 65	
cagtctgtgt tgacgcagcc gcc	23
<210> 66	
<211> 23	
<212> DNA	
<213> Artificial Sequence	
<220>	
<221>primer_bind	
<223>Degenerate Jlambda reverse primer useful for amplifying human VL domains	
<400> 66	
cagtctgccc tgactcagcc tgc	23
<210> 67	
<211> 23	
<212> DNA	
<213> Artificial Sequence	
<220>	
<221>primer_bind	
<223>Degenerate Jlambda reverse primer useful for amplifying human VL domains	
<400> 67	
tcttatgtgc tgactcagcc acc	23
<210> 68	
<211> 23	
<212> DNA	
<213> Artificial Sequence	
<220>	
<221>primer_bind	
<223>Degenerate Jlambda reverse primer useful for amplifying human VL domains	
<400> 68	
tcttctgagc tgactcagga ccc	23
<210> 69	
<211> 23	
<212> DNA	
<213> Artificial Sequence	
<220>	

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
 Garrett & Dunner, L.L.P.
 901 New York Avenue, N.W.
 Washington, D.C. 20001-4413

```

<221>primer_bind
<223>Degenerate Jlambda reverse primer useful for amplifying human VL domains

<400> 69
cacgttatac tgactcaacc gcc                                23

<210> 70
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate Jlambda reverse primer useful for amplifying human VL domains

<400> 70
caggctgtgc tcactcagcc gtc                                23

<210> 71
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate Jlambda reverse primer useful for amplifying human VL domains

<400> 71
aatttatgc tgactcagcc cca                                23

<210> 72
<211> 15
<212> PRT
<213> Artificial Sequence
<220>
<221>turn
<223>Linker peptide that may be used to join VH and VL domains in an scFv.

<400> 72
Gly Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser
 1           5           10          15

<210> 73
<211> 733
<212> DNA
<213> Homo sapiens

<400> 73
gggatccgga gccccaaatct tctgacaaaaa ctcacacatg cccaccgtgc ccagcacctg      60
aattcgaggg tgcaccgtca gtcttcctct tccccccaaa acccaaggac accctcatga      120
tctcccgac tcctgaggc acatgcgtgg tggtgacgt aagccacgaa gaccctgagg      180

```

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

tcaagttcaa ctggtaacgtg gacggcgtgg aggtgcataa tgccaagaca aagccgcggg	240
aggagcagta caacagcacg taccgtgtgg tcagcgtcct caccgtcctg caccaggact	300
ggctgaatgg caaggagtac aagtgcagg tctccaacaa agccctccca acccccattcg	360
agaaaaccat ctccaaagcc aaagggcagc cccgagaacc acaggtgtac accctgcccc	420
catccccggga tgagctgacc aagaaccagg tcagcctgac ctgcctggc aaaggcttct	480
atccaagcga catcggcgtg gagtgggaga gcaatggca gccggagaac aactacaaga	540
ccacgcctcc cgtgctggac tccgacggct ccttcttcct ctacagcaag ctcaccgtgg	600
acaagagcag gtggcagcag gggAACGTCT tctcatgctc cgtgatgcat gaggctctgc	660
acaaccacta cacgcagaag agcctctccc tgtctccggg taaatgagtg cgacggccgc	720
gactcttagag gat	733
<210> 74	
<211> 5	
<212> PRT	
<213> Artificial sequence	
<220>	
<221> misc_structure	
<223> membrane proximal motif of class 1 cytokine receptors	
<220>	
<221> misc_feature	
<222> (3)	
<223> Xaa equals any	
<400> 74	
Trp Ser Xaa Trp Ser	
1 5	
<210> 75	
<211> 86	
<212> DNA	
<213> Artificial Sequence	
<220>	
<221> primer_bind	
<223> forward primer useful for generation of a synthetic gamma activation site (GAS) containing promoter element	
<400> 75	
gcgcctcgag atttccccga aatctagatt tccccgaaat gatttcccg aatgatttc	60
cccgaaatat ctgccatctc aattag	86
<210> 76	
<211> 27	

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

```

<212> DNA
<213> Artificial Sequence
<220>
<221> primer_bind
<223> reverse primer useful for generation of a synthetic gamma activation
site (GAS) containing promoter element

<400> 76
gcccccaagct ttttgcaaag ccttaggc                                         27

<210> 77
<211> 271
<212> DNA
<213> Artificial Sequence
<220>
<221> misc_feature
<223> Synthetic GAS-SV40 promoter sequence

<400> 77
ctcgagattt ccccgaaatc tagatttccc cgaaatgattt tcccccggaaat gatttccccg      60
aaatatctgc catctcaattt agtcagcaac catagtcggccccc cccctaactc cgcccatcccc   120
gccccctaactt ccggccaggattt ccggccatcc tccggcccat ggctgactaa ttttttttat    180
ttatgcagag gccgaggccg cctcggccctc tgagctattt cagaagtatgtt gaggaggctt     240
ttttggaggc cttaggctttt gcaaaaagct t                                         271

<210> 78
<211> 32
<212> DNA
<213> Artificial Sequence
<220>
<221> primer_bind
<223> primer useful for generation of a EGR/SEAP reporter construct

<400> 78
gcgcgtcgagg gatgacagcg atagaacccc gg                                         32

<210> 79
<211> 31
<212> DNA
<213> Artificial Sequence
<220>
<221> primer_bind
<223> primer useful for generation of a EGR/SEAP reporter construct

<400> 79
gcgaagcttc gcgactcccc ggatccgcctt c                                         31

```

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

```

<210> 80
<211> 12
<212> DNA
<213> Artificial Sequence
<220>
<221> misc_binding
<223> NF-KB binding site

<400> 80
ggggacttcc 12

<210> 81
<211> 73
<212> DNA
<213> Artificial Sequence
<220>
<221> primer_bind
<223> forward primer useful for generation of a vector containing the NF-KB
promoter element

<400> 81
gcggcctcgaa ggggacttcc ccggggactt tccggggact ttccgggact ttccatcctg 60
ccatctcaat tag 73

<210> 82
<211> 256
<212> DNA
<213> Artificial Sequence
<220>
<221> misc_feature
<223> Synthetic NF-KB/SV40 promoter

<400> 82
ctcgaggggaa ctttccccggg gactttccgg ggactttccg ggactttcca tctgccatct 60
caatttagtca gcaaccatag tccccccct aactccgccc atcccccccc taactccgccc 120
cagttccgccc cattctccgc cccatggctg actaattttt tttatattatg cagaggccga 180
ggccgcctcg gcctctgagc tattccagaa gtatgtgagga ggcttttttg gaggcctagg 240
cttttgcaaa aagctt 256

```

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898*

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

JAN 04 2006

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. 6,926,898
APPLICATION NO.: 09/832,929
ISSUE DATE: August 9, 2005
INVENTOR(S): Craig A. Rosen and William A. Haseltine

Page 1 of 35

It is hereby certified that an error or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Under item (60) (Related U.S. Application Data) of the title page, delete the text beginning with "Provisional application No. 60/256,931" to and ending "provisional application No. 60/229,358, filed on Apr. 12, 2000."

Under item (56) (References Cited) of the title page and under U.S. PATENT DOCUMENTS beginning on page 1, insert:

--	2003-0022308 A1	1/2003	Fleer et al.
	2003-0036170 A1	2/2003	Fleer et al.
	2003-0036171 A1	2/2003	Fleer et al.
	2003-0036172 A1	2/2003	Fleer et al.
	2003-0054554 A1	3/2003	Becquart et al.
	2003-0082747 A1	5/2003	Fleer et al.
	2003-0104578 A1	10/2001	Ballance
	2004-0010134 A1	4/2001	Rosen et al.
	09/832,501	4/2001	Ballance et al.
	09/833,041	4/2001	Rosen et al.
	09/833,111	4/2001	Rosen et al.
	09/833,117	4/2001	Rosen et al.
	09/833,118	4/2001	Rosen et al.
	10/702,536	11/2003	Fleer et al.
	10/702,636	11/2003	Fleer et al.
			--

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

JAN 04 2006

Under item (56) (References Cited) of the title page and under OTHER PUBLICATIONS beginning on page 1, insert:

- Larsson, M., et al., "Role of Annexins in Endocytosis of Antigens in Immature Human Dendritic Cells," *Immunology* 92:501-511 (1997).
- Latta, M. et al., "Synthesis and Purification of Mature Human Serum Albumin From *E. Coli*," *Bio/Technology* 5:1309-1314 (1987).
- Latta, M., et al., "Tryptophan Promoter Derivatives on Multicopy Plasmids: A Comparative Analysis of Expression Potentials in *Escherichia coli*," *DNA and Cell Biology* 9:129-137 (1990).
- Lawn, R.M., et al., "The Sequence of Human Serum Albumin cDNA and its Expression in *E. coli*," *Nucleic Acids Research* 9:6103-6113 (1981).
- Le Bras, M., et al., "Epidemiologie et Clinique des Maladies Tropicales D'importation," *La Revue de Medicine Interne* 13:205-210 (1992), with English translation.
- Leblois, H., et al., "Stable Transduction of Actively Dividing Cells via a Novel Adenoviral/Episomal Vector," *Molecular Therapy* 1:314-322 (2000).
- Lee, C-H., et al., "Sodium Pertechnetate Tc99m Antral Scan in the Diagnosis of Retained Gastric Antrum," *Arch. Surg.* 119: 309-311 (1984).
- Lee, C-L., et al., "Preparation and Characterization of Polyethylene-Glycol-Modified Salmon Calcitonins," *Pharmaceutical Development and Technology*, 4(2): 269-275 (1999).
- Lee, W-C., et al., "Identification and Characterization of a Nuclear Localization Sequence-Binding Protein in Yeast," *Proc. Natl. Acad. Sci. USA* 86:8808-8812 (1989).
- Lee, Y-H., et al., "Comparison of Effective Renal Plasma Flow (ERPF) and Endogenous Creatinine Clearance (Ccr) in Evaluation of the Differential Kidney Function: An in Vivo Study," *Chin. Med. J. (Taipei)* 49:147-152 (1992).
- Lei, H-Y., et al., "An Antigen-specific Hypersensitivity Which Does Not Fit Into Traditional Classification of Hypersensitivity," *The Journal of Immunology* 143:432-438 (1989).
- Levitt, D., et al., "Toxicity of Perfluorinated Fatty-Acids for Human and Murine B Cell Lines," *Toxicology and Applied Pharmacology* 86:1-11 (1986).

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

Lew D.B., et al., "Mitogenic Effect of Lysosomal Hydrolases on Bovine Tracheal Myocytes in Culture," *The Journal of Clinical Investigation* 88:1969-1975 (1991).

Lewis, C., et al., "Is Sexual Dysfunction in Hypertensive Women Uncommon or Understudied?" *American Jour of Hypertension*, 11:733-735 (1998). --

Under item (57) (ABSTRACT) of the title page, "disordrs" should read --disorders--.

In the Specification

Col. 143, line 26, delete "As exhibited in Table 2, most", and insert --Most--.

Col. 143, line 31, delete "Table 2".

In the Claims

Col. 340, line 40, delete "an".

Col. 340, line 47, delete "an".

In the Sequence Listing

Delete the Sequence Listing beginning in Col. 299, beginning with the text "<160> NUMBER OF SEQ ID NOS: 72" to and ending "<400> SEQUENCE: 72"

Gly Gly Gly Ser Gly Gly Ser Gly Gly Gly Ser
1 5 10 15"

in Col. 340 and insert the following Sequence Listing:

```
<160> NUMBER OF SEQ ID NOS: 82

<210> 1
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<221> primer_bind
<223> primer useful to clone human growth hormone cDNA

<400> 1
cccaagaatt cccttatcca ggc 23

<210> 2
<211> 33
<212> DNA
<213> Artificial Sequence
<220>
<221> primer_bind
```

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

<223> primer useful to clone human growth hormone cDNA	
<400> 2 gggaagctta gaagccacag gatccctcca cag	33
<210> 3 <211> 16 <212> DNA <213> Artificial Sequence <220> <221> misc_structure <223> synthetic oligonucleotide used to join DNA fragments with non-cohesive ends.	
<400> 3 gataaaagatt cccaac	16
<210> 4 <211> 17 <212> DNA <213> Artificial Sequence <220> <221> misc_structure <223> synthetic oligonucleotide used to join DNA fragments with non-cohesive ends.	
<400> 4 aattgttggg aatcttt	17
<210> 5 <211> 17 <212> DNA <213> Artificial Sequence <220> <221> misc_structure <223> synthetic oligonucleotide used to join DNA fragments with non-cohesive ends.	
<400> 5 ttaggcttat tcccaac	17
<210> 6 <211> 18 <212> DNA <213> Artificial Sequence <220> <221> misc_structure <223> synthetic oligonucleotide used to join DNA fragments with non-cohesive ends.	
<400> 6 aattgttggg aataagcc	18

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

<210> 7
<211> 24
<212> PRT
<213> Artificial Sequence
<220>
<221> SITE
<222> 1)...(19)
<223> invertase leader sequence
<220>
<221> SITE
<222> 20)...(24)
<223> first 5 amino acids of mature human serum albumin

<400> 7
Met Leu Leu Gln Ala Phe Leu Phe Leu Leu Ala Gly Phe Ala Ala Lys
1 5 10 15

Ile Ser Ala Asp Ala His Lys Ser
20

<210> 8
<211> 21
<212> DNA
<213> Artificial Sequence
<220>
<221> misc_structure
<223> synthetic oligonucleotide used to join DNA fragments with non-cohesive ends.

<400> 8
gagatgcaca cctgagttag g 21

<210> 9
<211> 27
<212> DNA
<213> Artificial Sequence
<220>
<221> misc_structure
<223> synthetic oligonucleotide used to join DNA fragments with non-cohesive ends.

<400> 9
gatcctgtgg cttcgatgca cacaaga 27

<210> 10
<211> 24
<212> DNA
<213> Artificial Sequence
<220>
<221> misc_structure
<223> synthetic oligonucleotide used to join DNA fragments with non-cohesive ends.

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

JAN 04 2006

<400> 10	
ctcttgttg catcgaagcc acag	24
<210> 11	
<211> 30	
<212> DNA	
<213> Artificial Sequence	
<220>	
<221> misc_structure	
<223> synthetic oligonucleotide used to join DNA fragments with non-cohesive ends.	
<400> 11	
tgtggaaagag cctcagaatt tattcccaac	30
<210> 12	
<211> 31	
<212> DNA	
<213> Artificial Sequence	
<220>	
<221> misc_structure	
<223> synthetic oligonucleotide used to join DNA fragments with non-cohesive ends.	
<400> 12	
aattgttggg aataaaattct gaggcttttc c	31
<210> 13	
<211> 47	
<212> DNA	
<213> Artificial Sequence	
<220>	
<221> misc_structure	
<223> synthetic oligonucleotide used to join DNA fragments with non-cohesive ends.	
<400> 13	
ttaggcttag gtggcggtgg atccggcggt ggtggatctt tcccaac	47
<210> 14	
<211> 48	
<212> DNA	
<213> Artificial Sequence	
<220>	
<221> misc_structure	
<223> synthetic oligonucleotide used to join DNA fragments with non-cohesive ends.	
<400> 14	
aattgttggg aaagatccac caccgcggta tccaccgcac cctaagcc	48

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

JAN 04 2006

```

<210> 15
<211> 62
<212> DNA
<213> Artificial Sequence
<220>
<221> misc_structure
<223> synthetic oligonucleotide used to join DNA
fragments with non-cohesive ends.

<400> 15
ttaggcttag gcgggtgg atctgggtgc ggccggatctg gtggcggtgg atccttccca 60
ac 62

<210> 16
<211> 63
<212> DNA
<213> Artificial Sequence
<220>
<221> misc_structure
<223> synthetic oligonucleotide used to join DNA
fragments with non-cohesive ends.

<400> 16
aattgttggg aaggatccac cgccaccaga tccgcgcaca ccagatccac caccgcctaa 60
gcc 63

<210> 17
<211> 1782
<212> DNA
<213> Homo sapiens
<220>
<221> CDS
<222> (1)...(1755)

<400> 17
gat gca cac aag agt gag gtt gct cat cgg ttt aaa gat ttg gga gaa 48
Asp Ala His Lys Ser Glu Val Ala His Arg Phe Lys Asp Leu Gly Glu
1 5 10 15

gaa aat ttc aaa gcc ttg gtg ttg att gcc ttt gct cag tat ctt cag 96
Glu Asn Phe Lys Ala Leu Val Leu Ile Ala Phe Ala Gln Tyr Leu Gln
20 25 30

cag tgt cca ttt gaa gat cat gta aaa tta gtg aat gaa gta act gaa 144
Gln Cys Pro Phe Glu Asp His Val Lys Leu Val Asn Glu Val Thr Glu
35 40 45

ttt gca aaa aca tgt gtt gct gat gag tca gct gaa aat tgt gac aaa 192
Phe Ala Lys Thr Cys Val Ala Asp Glu Ser Ala Glu Asn Cys Asp Lys
50 55 60

```

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

tca ctt cat acc ctt ttt gga gac aaa tta tgc aca gtc gca act ctt			240
Ser Leu His Thr Leu Phe Gly Asp Lys Leu Cys Thr Val Ala Thr Leu			
65	70	75	80
cgt gaa acc tat ggt gaa atg gct gac tgc tgt gca aaa caa gaa cct			288
Arg Glu Thr Tyr Gly Glu Met Ala Asp Cys Cys Ala Lys Gln Glu Pro			
85	90	95	
gag aga aat gaa tgc ttc ttg caa cac aaa gat gac aac cca aac ctc			336
Glu Arg Asn Glu Cys Phe Leu Gln His Lys Asp Asp Asn Pro Asn Leu			
100	105	110	
ccc cga ttg gtg aga cca gag gtt gat gtg atg tgc act gct ttt cat			384
Pro Arg Leu Val Arg Pro Glu Val Asp Val Met Cys Thr Ala Phe His			
115	120	125	
gac aat gaa gag aca ttt ttg aaa aaa tac tta tat gaa att gcc aga			432
Asp Asn Glu Glu Thr Phe Leu Lys Lys Tyr Leu Tyr Glu Ile Ala Arg			
130	135	140	
aga cat cct tac ttt tat gcc ccg gaa ctc ctt ttc ttt gct aaa agg			480
Arg His Pro Tyr Phe Tyr Ala Pro Glu Leu Leu Phe Ala Lys Arg			
145	150	155	160
tat aaa gct gct ttt aca gaa tgt tgc caa gct gct gat aaa gct gcc			528
Tyr Lys Ala Ala Phe Thr Glu Cys Cys Gln Ala Ala Asp Lys Ala Ala			
165	170	175	
tgc ctg ttg cca aag ctc gat gaa ctt cg gat gaa ggg aag gct tcg			576
Cys Leu Leu Pro Lys Leu Asp Glu Leu Arg Asp Glu Gly Lys Ala Ser			
180	185	190	
tct gcc aaa cag aga ctc aaa tgt gcc agt ctc caa aaa ttt gga gaa			624
Ser Ala Lys Gln Arg Leu Lys Cys Ala Ser Leu Gln Lys Phe Gly Glu			
195	200	205	
aga gct ttc aaa gca tgg gca gtg gct cgc ctg agc cag aga ttt ccc			672
Arg Ala Phe Lys Ala Trp Ala Val Ala Arg Leu Ser Gln Arg Phe Pro			
210	215	220	
aaa gct gag ttt gca gaa gtt tcc aag tta gtg aca gat ctt acc aaa			720
Lys Ala Glu Phe Ala Glu Val Ser Lys Leu Val Thr Asp Leu Thr Lys			
225	230	235	240
gtc cac acg gaa tgc tgc cat gga gat ctg ctt gaa tgt gct gat gac			768
Val His Thr Glu Cys Cys His Gly Asp Leu Leu Glu Cys Ala Asp Asp			
245	250	255	
agg gcg gac ctt gcc aag tat atc tgt gaa aat cag gat tcg atc tcc			816
Arg Ala Asp Leu Ala Lys Tyr Ile Cys Glu Asn Gln Asp Ser Ile Ser			
260	265	270	

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

JAN 04 2006

agt aaa ctg aag gaa tgc tgt gaa aaa cct ctg ttg gaa aaa tcc cac		864	
Ser Lys Leu Lys Glu Cys Cys Glu Lys Pro Leu Leu Glu Lys Ser His			
275	280	285	
tgc att gcc gaa gtg gaa aat gat gag atg cct gct gac ttg cct tca		912	
Cys Ile Ala Glu Val Glu Asn Asp Glu Met Pro Ala Asp Leu Pro Ser			
290	295	300	
tta gct gct gat ttt gtt gaa agt aag gat gtt tgc aaa aac tat gct		960	
Leu Ala Ala Asp Phe Val Glu Ser Lys Asp Val Cys Lys Asn Tyr Ala			
305	310	315	320
gag gca aag gat gtc ttc ctg ggc atg ttt ttg tat gaa tat gca aga		1008	
Glu Ala Lys Asp Val Phe Leu Gly Met Phe Leu Tyr Glu Tyr Ala Arg			
325	330	335	
agg cat cct gat tac tct gtc gtg ctg ctg aga ctt gcc aag aca		1056	
Arg His Pro Asp Tyr Ser Val Val Leu Leu Arg Leu Ala Lys Thr			
340	345	350	
tat gaa acc act cta gag aag tgc tgt gcc gct gca gat cct cat gaa		1104	
Tyr Glu Thr Thr Leu Glu Lys Cys Cys Ala Ala Asp Pro His Glu			
355	360	365	
tgc tat gcc aaa gtg ttc gat gaa ttt aaa cct ctt gtg gaa gag cct		1152	
Cys Tyr Ala Lys Val Phe Asp Glu Phe Lys Pro Leu Val Glu Glu Pro			
370	375	380	
cag aat tta atc aaa caa aac tgt gag ctt ttt gag cag ctt gga gag		1200	
Gln Asn Leu Ile Lys Gln Asn Cys Glu Leu Phe Glu Gln Leu Gly Glu			
385	390	395	400
tac aaa ttc cag aat gcg cta tta gtt cgt tac acc aag aaa gta ccc		1248	
Tyr Lys Phe Gln Asn Ala Leu Leu Val Arg Tyr Thr Lys Lys Val Pro			
405	410	415	
caa gtg tca act cca act ctt gta gag gtc tca aga aac cta gga aaa		1296	
Gln Val Ser Thr Pro Thr Leu Val Glu Val Ser Arg Asn Leu Gly Lys			
420	425	430	
gtg ggc agc aaa tgt tgt aaa cat cct gaa gca aaa aga atg ccc tgt		1344	
Val Gly Ser Lys Cys Cys Lys His Pro Glu Ala Lys Arg Met Pro Cys			
435	440	445	
gca gaa gac tat cta tcc gtg gtc ctg aac cag tta tgt gtg ttg cat		1392	
Ala Glu Asp Tyr Leu Ser Val Val Leu Asn Gln Leu Cys Val Leu His			
450	455	460	
gag aaa acg cca gta agt gac aga gtc aca aaa tgc tgc aca gag tcc		1440	
Glu Lys Thr Pro Val Ser Asp Arg Val Thr Lys Cys Cys Thr Glu Ser			
465	470	475	480

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

JAN 04 2006

ttg gtg aac agg cga cca tgc ttt tca gct ctg gaa gtc gat gaa aca	485	490	495	1488
Leu Val Asn Arg Arg Pro Cys Phe Ser Ala Leu Glu Val Asp Glu Thr				
tac gtt ccc aaa gag ttt aat gct gaa aca ttc acc ttc cat gca gat	500	505	510	1536
Tyr Val Pro Lys Glu Phe Asn Ala Glu Thr Phe Thr Phe His Ala Asp				
ata tgc aca ctt tct gag aag gag aga caa atc aag aaa caa act gca	515	520	525	1584
Ile Cys Thr Leu Ser Glu Lys Glu Arg Gln Ile Lys Lys Gln Thr Ala				
ctt gtt gag ctt gtg aaa cac aag ccc aag gca aca aaa gag caa ctg	530	535	540	1632
Leu Val Glu Leu Val Lys His Lys Pro Lys Ala Thr Lys Glu Gln Leu				
aaa gct gtt atg gat gat ttc gca gct ttt gta gag aag tgc tgc aag	545	550	555	1680
Lys Ala Val Met Asp Asp Phe Ala Ala Phe Val Glu Lys Cys Cys Lys				
gct gac gat aag gag acc tgc ttt gcc gag gag ggt aaa aaa ctt gtt	565	570	575	1728
Ala Asp Asp Lys Glu Thr Cys Phe Ala Glu Glu Gly Lys Lys Leu Val				
gct gca agt caa gct gcc tta ggc tta taacatctac atttaaaagc atctcag	580	585		1782
Ala Ala Ser Gln Ala Ala Leu Gly Leu				
<210> 18				
<211> 585				
<212> PRT				
<213> Homo Sapiens				
<400> 18				
Asp Ala His Lys Ser Glu Val Ala His Arg Phe Lys Asp Leu Gly Glu	1	5	10	15
Glu Asn Phe Lys Ala Leu Val Leu Ile Ala Phe Ala Gln Tyr Leu Gln	20	25	30	
Gln Cys Pro Phe Glu Asp His Val Lys Leu Val Asn Glu Val Thr Glu	35	40	45	
Phe Ala Lys Thr Cys Val Ala Asp Glu Ser Ala Glu Asn Cys Asp Lys	50	55	60	
Ser Leu His Thr Leu Phe Gly Asp Lys Leu Cys Thr Val Ala Thr Leu	65	70	75	80
Arg Glu Thr Tyr Gly Glu Met Ala Asp Cys Cys Ala Lys Gln Glu Pro	85	90	95	

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

Glu	Arg	Asn	Glu	Cys	Phe	Leu	Gln	His	Lys	Asp	Asp	Asn	Pro	Asn	Leu
100															110
Pro	Arg	Leu	Val	Arg	Pro	Glu	Val	Asp	Val	Met	Cys	Thr	Ala	Phe	His
115															125
Asp	Asn	Glu	Glu	Thr	Phe	Leu	Lys	Lys	Tyr	Leu	Tyr	Glu	Ile	Ala	Arg
130															140
Arg	His	Pro	Tyr	Phe	Tyr	Ala	Pro	Glu	Leu	Leu	Phe	Ala	Lys	Arg	
145															160
Tyr	Lys	Ala	Ala	Phe	Thr	Glu	Cys	Cys	Gln	Ala	Ala	Asp	Lys	Ala	Ala
165															175
Cys	Leu	Leu	Pro	Lys	Leu	Asp	Glu	Leu	Arg	Asp	Glu	Gly	Lys	Ala	Ser
180															190
Ser	Ala	Lys	Gln	Arg	Leu	Lys	Cys	Ala	Ser	Leu	Gln	Lys	Phe	Gly	Glu
195															205
Arg	Ala	Phe	Lys	Ala	Trp	Ala	Val	Ala	Arg	Leu	Ser	Gln	Arg	Phe	Pro
210															220
Lys	Ala	Glu	Phe	Ala	Glu	Val	Ser	Lys	Leu	Val	Thr	Asp	Leu	Thr	Lys
225															240
Val	His	Thr	Glu	Cys	Cys	His	Gly	Asp	Leu	Leu	Glu	Cys	Ala	Asp	Asp
245															255
Arg	Ala	Asp	Leu	Ala	Lys	Tyr	Ile	Cys	Glu	Asn	Gln	Asp	Ser	Ile	Ser
260															270
Ser	Lys	Leu	Lys	Glu	Cys	Cys	Glu	Lys	Pro	Leu	Leu	Glu	Lys	Ser	His
275															285
Cys	Ile	Ala	Glu	Val	Glu	Asn	Asp	Glu	Met	Pro	Ala	Asp	Leu	Pro	Ser
290															300
Leu	Ala	Ala	Asp	Phe	Val	Glu	Ser	Lys	Asp	Val	Cys	Lys	Asn	Tyr	Ala
305															320
Glu	Ala	Lys	Asp	Val	Phe	Leu	Gly	Met	Phe	Leu	Tyr	Glu	Tyr	Ala	Arg
325															335
Arg	His	Pro	Asp	Tyr	Ser	Val	Val	Leu	Leu	Arg	Leu	Ala	Lys	Thr	
340															350
Tyr	Glu	Thr	Thr	Leu	Glu	Lys	Cys	Cys	Ala	Ala	Asp	Pro	His	Glu	
355															365

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

Cys	Tyr	Ala	Lys	Val	Phe	Asp	Glu	Phe	Lys	Pro	Leu	Val	Glu	Glu	Pro
370															
														380	
Gln	Asn	Leu	Ile	Lys	Gln	Asn	Cys	Glu	Leu	Phe	Glu	Gln	Leu	Gly	Glu
385															400
Tyr	Lys	Phe	Gln	Asn	Ala	Leu	Leu	Val	Arg	Tyr	Thr	Lys	Lys	Val	Pro
														415	
405															
Gln	Val	Ser	Thr	Pro	Thr	Leu	Val	Glu	Val	Ser	Arg	Asn	Leu	Gly	Lys
														430	
420															
Val	Gly	Ser	Lys	Cys	Cys	Lys	His	Pro	Glu	Ala	Lys	Arg	Met	Pro	Cys
														445	
435															
Ala	Glu	Asp	Tyr	Leu	Ser	Val	Val	Leu	Asn	Gln	Leu	Cys	Val	Leu	His
														460	
450															
Glu	Lys	Thr	Pro	Val	Ser	Asp	Arg	Val	Thr	Lys	Cys	Cys	Thr	Glu	Ser
														480	
465															
Leu	Val	Asn	Arg	Arg	Pro	Cys	Phe	Ser	Ala	Leu	Glu	Val	Asp	Glu	Thr
														495	
485															
Tyr	Val	Pro	Lys	Glu	Phe	Asn	Ala	Glu	Thr	Phe	Thr	Phe	His	Ala	Asp
														510	
500															
Ile	Cys	Thr	Leu	Ser	Glu	Lys	Glu	Arg	Gln	Ile	Lys	Lys	Gln	Thr	Ala
														525	
515															
Leu	Val	Glu	Leu	Val	Lys	His	Lys	Pro	Lys	Ala	Thr	Lys	Glu	Gln	Leu
														540	
530															
Lys	Ala	Val	Met	Asp	Asp	Phe	Ala	Ala	Phe	Val	Glu	Lys	Cys	Cys	Lys
														560	
545															
Ala	Asp	Asp	Lys	Glu	Thr	Cys	Phe	Ala	Glu	Glu	Gly	Lys	Lys	Leu	Val
														575	
565															
Ala	Ala	Ser	Gln	Ala	Ala	Leu	Gly	Leu							
														585	
580															
<210>	19														
<211>	58														
<212>	DNA														
<213>	Artificial Sequence														
<220>															
<221>	primer_bind														
<223>	primer used to generate XhoI and ClaI site in pPPC0006														
<400>	19														
gcctcgagaa	aagagatgca	cacaagagtg	aggttgctca	tcgatttaaa	gatttggg										58

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

```

<210> 20
<211> 59
<212> DNA
<213> Artificial Sequence
<220>
<221> primer_bind
<223> primer used in generation XhoI and ClaI site in pPPC0006

<400> 20
aatcgatgag caacctcaact cttgtgtgca tctctttct cgaggctcct ggaataa 59

<210> 21
<211> 24
<212> DNA
<213> Artificial Sequence
<220>
<221> primer_bind
<223> primer used in generation XhoI and ClaI site in pPPC0006

<400> 21
tacaaactta agagtccaaat tagc 24

<210> 22
<211> 29
<212> DNA
<213> Artificial Sequence
<220>
<221> primer_bind
<223> primer used in generation XhoI and ClaI site in pPPC0006

<400> 22
cacttctcta gagtggttc atatgtctt 29

<210> 23
<211> 60
<212> DNA
<213> Artificial Sequence
<220>
<221> Misc_Structure
<223> Synthetic oligonucleotide used to alter restriction sites in pPPC0007

<400> 23
aagctgcctt aggcttataa taaggcgcgccg cggccggccg tttaaactaa gcttaattct 60

<210> 24
<211> 60
<212> DNA
<213> Artificial Sequence
<220>
<221> Misc_Structure
<223> Synthetic oligonucleotide used to alter restriction sites in pPPC0007

```

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
 Garrett & Dunner, L.L.P.
 901 New York Avenue, N.W.
 Washington, D.C. 20001-4413

JAN 04 2006

<400> 24
agaatthaagc ttagttaaa cggccggccg gcgcgcctta ttataaggcctt aaggcagctt 60

<210> 25
<211> 32
<212> DNA
<213> Artificial Sequence
<220>
<221> primer_bind
<223> forward primer useful for generation of albumin fusion protein in which the albumin moiety is N-terminal of the Therapeutic Protein
<220>
<221> misc feature
<222> (18)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (19)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (20)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (21)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (22)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (23)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (24)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (25)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (26)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (27)
<223> n equals a,t,g, or c
<220>

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

JAN 04 2005

```
<221> misc feature
<222> (28)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (29)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (30)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (31)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (32)
<223> n equals a,t,g, or c

<400> 25
aagctgcctt aggcttannn nnnnnnnnnn nn
```

32

```
<210> 26
<211> 51
<212> DNA
<213> Artificial Sequence
<220>
<221> primer_bind
<223> reverse primer useful for generation of albumin fusion protein in which
the albumin moiety is N-terminal of the Therapeutic Protein
<220>
<221> misc feature
<222> (37)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (38)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (39)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (40)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (41)
<223> n equals a,t,g, or c
<220>
```

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

JAN 04 2006

```
<221> misc feature
<222> (42)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (43)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (44)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (45)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (46)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (47)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (48)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (49)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (50)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (51)
<223> n equals a,t,g, or c

<400> 26
gcgcgcgtt aaacggccgg ccggcgcgcc ttattannnn nnnnnnnnnn n 51

<210> 27
<211> 33
<212> DNA
<213> Artificial Sequence
<220>
<223> forward primer useful for generation of albumin fusion protein in which
the albumin moiety is c-terminal of the Therapeutic Protein
<220>
<221> misc feature
```

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

JAN 04 2006

```
<222> (19)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (20)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (21)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (22)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (23)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (24)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (25)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (26)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (27)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (28)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (29)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (30)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (31)
<223> n equals a,t,g, or c
<220>
<221> misc feature
```

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

JAN 04 2006

```
<222> (32)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (33)
<223> n equals a,t,g, or c

<400> 27
aggagcgtcg acaaaagann nnnnnnnnnn nnn

<210> 28
<211> 52
<212> DNA
<213> Artificial Sequence
<220>
<221> primer_bind
<223> reverse primer useful for generation of albumin fusion protein in which
the albumin moiety is c-terminal of the Therapeutic Protein
<220>
<221> misc feature
<222> (38)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (39)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (40)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (41)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (42)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (43)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (44)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (45)
<223> n equals a,t,g, or c
<220>
<221> misc feature
```

33

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

JAN 04 2006

```

<222> (46)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (47)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (48)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (49)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (50)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (51)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (52)
<223> n equals a,t,g, or c

<400> 28
ctttaaatcg atgagcaacc tcactcttgt gtgcattcnnn nnnnnnnnnn nn      52

<210> 29
<211> 24
<212> PRT
<213> Artificial Sequence
<220>
<221> signal
<223> signal peptide of natural human serum albumin protein

<400> 29
Met Lys Trp Val Ser Phe Ile Ser Leu Leu Phe Leu Phe Ser Ser Ala
    1          5           10          15

Tyr Ser Arg Ser Leu Asp Lys Arg
    20

<210> 30
<211> 114
<212> DNA
<213> Artificial Sequence
<220>
<221> primer_bind
<223> forward primer useful for generation of PC4:HSA albumin fusion VECTOR

```

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

JAN 04 2006

```

<220>
<221> misc_feature
<222> (5)..(10)
<223> BamHI restriction site
<220>
<221> misc_feature
<222> (11)..(16)
<223> Hind III restriction site
<220>
<221> misc_feature
<222> (17)..(27)
<223> Kozak sequence
<220>
<221> misc_feature
<222> (25)..(97)
<223> cds natural signal sequence of human serum albumin
<220>
<221> misc_feature
<222> (75)..(81)
<223> XbaI restriction site
<220>
<221> misc_feature
<222> (98)..(114)
<223> cds first six amino acids of human serum albumin

<400> 30
tcagggatcc aagcttccgc caccatgaag tggtaacct ttattttccct tccttttctc 60
tttagctcggtt actctcgag gggtgtgttt cgtcgagatg cacacaagag tgag 114

<210> 31
<211> 43
<212> DNA
<213> Artificial Sequence
<220>
<221> primer_bind
<223> reverse primer useful for generation of PC4:HSA albumin fusion VECTOR
<220>
<221> misc_feature
<222> (6)..(11)
<223> Asp718 restriction site
<220>
<221> misc_feature
<222> (12)..(17)
<223> EcoRI restriction site
<220>
<221> misc_feature
<222> (15)..(17)
<223> reverse complement of stop codon
<220>
<221> misc_feature
<222> (18)..(25)

```

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

JAN 04 2006

```
<223> AscI restriction site
<220>
<221> misc_feature
<222> (18)..(43)
<223> reverse complement of DNA sequence encoding last 9 amino acids

<400> 31
gcagcggta cgaattcgcc ggcgcctata agcctaaggc agc 43

<210> 32
<211> 46
<212> DNA
<213> Artificial Sequence
<220>
<221> primer_bind
<223> forward primer useful for inserting Therapeutic protein into pC4:HSA
vector
<220>
<221> misc feature
<222> (29)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (30)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (31)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (32)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (33)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (34)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (35)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (36)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (37)
```

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

JAN 04 2005

```
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (38)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (39)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (40)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (41)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (42)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (43)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (44)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (45)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (46)
<223> n equals a,t,g, or c

<400> 32
ccggcgctcg aggggtgtgt ttcgtcgann nnnnnnnnnn nnnnnn
```

46

```
<210> 33
<211> 55
<212> DNA
<213> Artificial Sequence
<220>
<221> primer_bind
<223> reverse primer useful for inserting Therapeutic protein into pC4:HSA
vector
<220>
<221> misc feature
<222> (38)
```

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

JAN 04 2006

```
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (39)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (40)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (41)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (42)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (43)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (44)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (45)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (46)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (47)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (48)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (49)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (50)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (51)
```

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (52)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (53)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (54)
<223> n equals a,t,g, or c
<220>
<221> misc feature
<222> (55)
<223> n equals a,t,g, or c

<400> 33

agtcccatcg atgagcaacc tcactttgt gtgcattcnnn nnnnnnnnnn nnnnn

55

<210> 34
<211> 17
<212> PRT
<213> Artificial Sequence
<220>
<221> signal
<223> Stanniocalcin signal peptide

<400> 34

Met Leu Gln Asn Ser Ala Val Leu Leu Leu Val Ile Ser Ala Ser Ala
1 5 10 15

<210> 35
<211> 22
<212> PRT
<213> Artificial Sequence
<220>
<221> signal
<223> Synthetic signal peptide

<400> 35

Met Pro Thr Trp Ala Trp Trp Leu Phe Leu Val Leu Leu Ala Leu
1 5 10 15

Trp Ala Pro Ala Arg Gly
20

<210> 36
<211> 23
<212> DNA
<213> Artificial Sequence
<220>

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

JAN 04 2006

```

<221>primer_bind
<223>Degenerate VH forward primer useful for amplifying human VH domains

<400> 36
caggtgcagc tggcagtc tgg 23

<210> 37
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate VH forward primer useful for amplifying human VH domains

<400> 37
caggtaact taaggagtc tgg 23

<210> 38
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate VH forward primer useful for amplifying human VH domains

<400> 38
gaggtgcagc tggggagtc tgg 23

<210> 39
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate VH forward primer useful for amplifying human VH domains

<400> 39
caggtgcagc tgcaggagtc ggg 23

<210> 40
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate VH forward primer useful for amplifying human VH domains

<400> 40
gaggtgcagc tggtgcagtc tgc 23

<210> 41
<211> 23

```

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

```

<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate VH forward primer useful for amplifying human VH domains

<400> 41
caggtacagc tgcacgcagtc agg 23

<210> 42
<211> 24
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate JH reverse primer useful for amplifying human VH domains

<400> 42
tgaggagacg gtgaccaggg tgcc 24

<210> 43
<211> 24
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate JH reverse primer useful for amplifying human VH domains

<400> 43
tgaagagacg gtgaccattg tccc 24

<210> 44
<211> 24
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate JH reverse primer useful for amplifying human VH domains

<400> 44
tgaggagacg gtgaccaggg ttcc 24

<210> 45
<211> 24
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate JH reverse primer useful for amplifying human VH domains

<400> 45
tgaggagacg gtgaccgtgg tccc 24

```

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

```
<210> 46  
<211> 23  
<212> DNA  
<213> Artificial Sequence  
<220>  
<221>primer_bind  
<223>Degenerate Vkappa forward primer useful for amplifying human VL domains  
  
<400> 46  
gacatccaga tgacccagtc tcc 23  
  
<210> 47  
<211> 23  
<212> DNA  
<213> Artificial Sequence  
<220>  
<221>primer_bind  
<223>Degenerate Vkappa forward primer useful for amplifying human VL domains  
  
<400> 47  
gatgttgtga tgactcagtc tcc 23  
  
<210> 48  
<211> 23  
<212> DNA  
<213> Artificial Sequence  
<220>  
<221>primer_bind  
<223>Degenerate Vkappa forward primer useful for amplifying human VL domains  
  
<400> 48  
gatattgtga tgactcagtc tcc 23  
  
<210> 49  
<211> 23  
<212> DNA  
<213> Artificial Sequence  
<220>  
<221>primer_bind  
<223>Degenerate Vkappa forward primer useful for amplifying human VL domains  
  
<400> 49  
gaaatttgt tgacgcagtc tcc 23  
  
<210> 50  
<211> 23  
<212> DNA  
<213> Artificial Sequence  
<220>  
<221>primer_bind  
<223>Degenerate Vkappa forward primer useful for amplifying human VL domains
```

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

JAN 04 2006

<400> 50	
gacatcgta tgaccaggc tcc	23
<210> 51	
<211> 23	
<212> DNA	
<213> Artificial Sequence	
<220>	
<221>primer_bind	
<223>Degenerate Vkappa forward primer useful for amplifying human VL domains	
<400> 51	
gaaacgacac tcacgcagtc tcc	23
<210> 52	
<211> 23	
<212> DNA	
<213> Artificial Sequence	
<220>	
<221>primer_bind	
<223>Degenerate Vkappa forward primer useful for amplifying human VL domains	
<400> 52	
gaaattgtgc tgactcagtc tcc	23
<210> 53	
<211> 23	
<212> DNA	
<213> Artificial Sequence	
<220>	
<221>primer_bind	
<223>Degenerate Vlambda forward primer useful for amplifying human VL domains	
<400> 53	
cagtctgtgt tgacgcagcc gcc	23
<210> 54	
<211> 23	
<212> DNA	
<213> Artificial Sequence	
<220>	
<221>primer_bind	
<223>Degenerate Vlambda forward primer useful for amplifying human VL domains	
<400> 54	
cagtctgccc tgactcagcc tgc	23
<210> 55	
<211> 23	
<212> DNA	
<213> Artificial Sequence	
<220>	

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
 Garrett & Dunner, L.L.P.
 901 New York Avenue, N.W.
 Washington, D.C. 20001-4413

```

<221>primer_bind
<223>Degenerate Vlambda forward primer useful for amplifying human VL domains

<400> 55
tcctatgtgc tgactcagcc acc 23

<210> 56
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<221>primer_bind
<223>Degenerate Vlambda forward primer useful for amplifying human VL domains

<400> 56
tcttctgagc tgactcagga ccc 23

<210> 57
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate Vlambda forward primer useful for amplifying human VL domains

<400> 57
cacgttatac tgactcaacc gcc 23

<210> 58
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate Vlambda forward primer useful for amplifying human VL domains

<400> 58
caggctgtgc tcactcagcc gtc 23

<210> 59
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate Vlambda forward primer useful for amplifying human VL domains

<400> 59
aattttatgc tgactcagcc cca 23

```

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
 Garrett & Dunner, L.L.P.
 901 New York Avenue, N.W.
 Washington, D.C. 20001-4413

```
<210> 60
<211> 24
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate J kappa reverse primer useful for amplifying human VL domains

<400> 60
acgtttgatt tccacaccttgg tccc
```

24

```
<210> 61
<211> 24
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate J kappa reverse primer useful for amplifying human VL domains

<400> 61
acgtttgatc tccagcttgg tccc
```

24

```
<210> 62
<211> 24
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate J kappa reverse primer useful for amplifying human VL domains

<400> 62
acgtttgata tccactttgg tccc
```

24

```
<210> 63
<211> 24
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate J kappa reverse primer useful for amplifying human VL domains

<400> 63
acgtttgatc tccacaccttgg tccc
```

24

```
<210> 64
<211> 24
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate J kappa reverse primer useful for amplifying human VL domains
```

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

<400> 64 acgttaatc tccagtcgtg tccc	24
<210> 65 <211> 23 <212> DNA <213> Artificial Sequence <220> <221>primer_bind <223>Degenerate Jlambda reverse primer useful for amplifying human VL domains	
<400> 65 cagtctgtgt tgacgcagcc gcc	23
<210> 66 <211> 23 <212> DNA <213> Artificial Sequence <220> <221>primer_bind <223>Degenerate Jlambda reverse primer useful for amplifying human VL domains	
<400> 66 cagtctgccc tgactcagcc tgc	23
<210> 67 <211> 23 <212> DNA <213> Artificial Sequence <220> <221>primer_bind <223>Degenerate Jlambda reverse primer useful for amplifying human VL domains	
<400> 67 tccttatgtgc tgactcagcc acc	23
<210> 68 <211> 23 <212> DNA <213> Artificial Sequence <220> <221>primer_bind <223>Degenerate Jlambda reverse primer useful for amplifying human VL domains	
<400> 68 tcttctgagc tgactcagga ccc	23
<210> 69 <211> 23 <212> DNA <213> Artificial Sequence <220>	

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

```

<221>primer_bind
<223>Degenerate Jlambda reverse primer useful for amplifying human VL domains

<400> 69
cacgttatac tgactcaacc gcc 23

<210> 70
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate Jlambda reverse primer useful for amplifying human VL domains

<400> 70
caggctgtgc tcactcagcc gtc 23

<210> 71
<211> 23
<212> DNA
<213> Artificial Sequence
<220>
<221>primer_bind
<223>Degenerate Jlambda reverse primer useful for amplifying human VL domains

<400> 71
aattttatgc tgactcagcc cca 23

<210> 72
<211> 15
<212> PRT
<213> Artificial Sequence
<220>
<221>turn
<223>Linker peptide that may be used to join VH and VL domains in an scFv.

<400> 72
Gly Gly Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser
    1           5           10          15

<210> 73
<211> 733
<212> DNA
<213> Homo sapiens

<400> 73
gggatccgga gccccaaatct tctgacaaaaa ctcacacatg cccaccgtgc ccagcacctg 60
aattcgaggg tgcaccgtca gtcttcctct tccccccaaa acccaaggac accctcatga 120
tctcccgac tcctgaggc acatgcgtgg tggtgacgt aagccacgaa gaccctgagg 180

```

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

tcaagttcaa ctggtaacgtg gacggcgtgg aggtgcataa tgccaagaca aagccgcggg	240
aggagcagta caacagcacg taccgtgtgg tcagcgtcct caccgtcctg caccaggact	300
ggctgaatgg caaggagtagc aagtgcagg tctccaacaa agccctccca acccccacatcg	360
agaaaaaccat ctccaaagcc aaagggcagc cccgagaacc acaggtgtac accctgcccc	420
catcccggga tgagctgacc aagaaccagg tcagcctgac ctgcctggtc aaaggcttct	480
atccaagcga catcgccgtg gagtgggaga gcaatggca gccggagaac aactacaaga	540
ccacgcctcc cgtgctggac tccgacggct ctttcttctt ctacagcaag ctcaccgtgg	600
acaagagcag gtggcagcag gggAACGTCT tctcatgctc cgtgatgcat gaggctctgc	660
acaaccacta cacgcagaag agcctctccc tgtctccggg taaaatgagtg cgacggccgc	720
gactctagag gat	733
<210> 74	
<211> 5	
<212> PRT	
<213> Artificial sequence	
<220>	
<221> misc_structure	
<223> membrane proximal motif of class 1 cytokine receptors	
<220>	
<221> misc_feature	
<222> (3)	
<223> Xaa equals any	
<400> 74	
Trp Ser Xaa Trp Ser	
1	5
<210> 75	
<211> 86	
<212> DNA	
<213> Artificial Sequence	
<220>	
<221> primer_bind	
<223> forward primer useful for generation of a synthetic gamma activation site (GAS) containing promoter element	
<400> 75	
gcgcctcgag atttccccga aatcttagatt tcccccgaat gatttcccccgaatgatttc	
60	
cccgaaatat ctgccatctc aattag	
86	
<210> 76	
<211> 27	

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

JAN 04 2006

<212> DNA		
<213> Artificial Sequence		
<220>		
<221> primer_bind		
<223> reverse primer useful for generation of a synthetic gamma activation site (GAS) containing promoter element		
<400> 76		
gcggcaagct ttttcaaag ccttagc		27
<210> 77		
<211> 271		
<212> DNA		
<213> Artificial Sequence		
<220>		
<221> misc_feature		
<223> Synthetic GAS-SV40 promoter sequence		
<400> 77		
ctcgagattt ccccgaaatc tagatttccc cgaaatgatt tccccgaaat gatttccccg		60
aaatatctgc catctcaatt agtcagcaac catagtcccg cccctaactc cgcccatccc		120
gcccctaact ccgcccagtt ccgcccattc tccgccccat ggctgactaa ttttttttat		180
ttatgcagag gccgaggccg cctcggcctc tgagctattc cagaagtatg gaggaggctt		240
ttttggaggc cttaggctttt gcaaaaagct t		271
<210> 78		
<211> 32		
<212> DNA		
<213> Artificial Sequence		
<220>		
<221> primer_bind		
<223> primer useful for generation of a EGR/SEAP reporter construct		
<400> 78		
gcgctcgagg gatgacagcg atagaacccc gg		32
<210> 79		
<211> 31		
<212> DNA		
<213> Artificial Sequence		
<220>		
<221> primer_bind		
<223> primer useful for generation of a EGR/SEAP reporter construct		
<400> 79		
gcgaagcttc gcgactcccc ggatccgcct c		31

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413

<210> 80		
<211> 12		
<212> DNA		
<213> Artificial Sequence		
<220>		
<221> misc_binding		
<223> NF-KB binding site		
<400> 80		
ggggactttc cc		12
<210> 81		
<211> 73		
<212> DNA		
<213> Artificial Sequence		
<220>		
<221> primer_bind		
<223> forward primer useful for generation of a vector containing the NF-KB promoter element		
<400> 81		
gcggcctcg a gggactttc ccggggactt tccgggact ttccggact ttccatcctg	60	
ccatctcaat tag		73
<210> 82		
<211> 256		
<212> DNA		
<213> Artificial Sequence		
<220>		
<221> misc_feature		
<223> Synthetic NF-KB/SV40 promoter		
<400> 82		
ctcgagggga cttcccccgg gacttccgg ggactttccg ggactttcca tctgccatct	60	
caattagtca gcaaccatag tcccggccct aactccgccc atcccgcccc taactccgcc	120	
cagttccgcc cattctccgc cccatggctg actaattttt tttatttatg cagaggccga	180	
ggccgcctcg gcctctgagc tattccagaa gtagtgagga ggctttttg gaggcctagg	240	
cttttgcaaa aagctt		256

MAILING ADDRESS OF SENDER

U.S. Patent No. 6,926,898

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
901 New York Avenue, N.W.
Washington, D.C. 20001-4413